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Chapter 1  
INTRODUCTION 
1.1 Host immunity 
The immune system is an elaborate and dynamic regulatory and 
communication network composed of many kinds of molecules, cells, tissues and 
organs responsible for host resistance against infections initiated by microbial 
pathogens. The immune system is subdivided into two arms, the innate and the 
adaptive. 
1.1.1 Innate Immunity 
The innate immune system is the first line of defense against invading 
microbial pathogens. Such pathogens first encounter an anatomical barrier which 
includes skin and internal epithelial layers, as well as the chemicals they secrete. 
Once the anatomical barrier is breached, cellular and humoral components of the 
innate immune system are engaged to eliminate the foreign body. The major cell 
types involved in innate immunity include: neutrophils, macrophages, eosinophils, 
basophils, mast cells, natural killer cells and dendritic cells. These cells identify 
pathogen-associated molecular patterns (PAMPs) through receptors on their 
surface that are called pattern-recognition receptors (PRRs) (Lee et al., 2012).  
PRRs are classified based on their ligand function, localization and/or 
evolutionary relationships. Based on their functions, PRRs can be classified into 
three families: secreted, endocytic and signaling PRRs. Secretory PRRs, 
including mannan binding lectin and C reactive protein, are secreted into the 
plasma and recognize bacterial cell components which enable them to activate 
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the complement pathway and phagocytic cells. Mannan binding lectin is 
produced in the liver and secreted into the bloodstream where it binds to 
carbohydrates on the surface of pathogens and activates the lectin pathway of 
the complement system (Worthley et al., 2005). The endocytic PRRs include 
mannose receptor, scavenger receptor and opsonin receptor. They are 
expressed at the surface of phagocytic cells, and function to mediate the 
recognition, engulfment and destruction of microbes and/or microbial moieties 
without intracellular signaling. Signaling PRRs, on the other hand, include Toll-
like receptors (TLR), nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLR) and retinoic acid inducible gene I (RIG)-1-like helicases (RLH) 
which are involved in cell activation in response to diverse microbial moieties. 
Signaling PRRs are found on the cell surface (e.g., TLR2, TLR4, TLR5, TLR1/2, 
and TLR2/6), associated with the endosomal membrane (e.g., TLR3, TLR7, 
TLR8 and TLR9) or in the cytoplasm (NOD and caspase activating and 
recruitment domain-containing proteins). They recognize specific microbial 
ligands including bacterial lipopolysaccharide (LPS), flagellin and lipopeptides 
(Jeannin et al., 2008). Upon activation, these receptors bind and activate the 
adaptor molecules to trigger myeloid differentiation primary response gene (88) 
product (MyD88) dependent and independent signaling pathways. This in turn 
subsequently activates the transcription factor, nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) which regulates immune gene responses 
and inflammation (Kawai and Akira, 2010). These together allow an immediate 
response against microbial infection and contribute to the initiation of long-lasting 
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adaptive immunity.  
1.1.2 Adaptive Immunity 
The adaptive immune system is composed of highly specialized, systemic 
cells, including macrophages, dendritic cells and T and B cells and associated 
processes that eliminate or prevent pathogen growth. Antigen presenting cells 
(APCs, including dendritic cells, B cells, and macrophages) initially process and 
present antigen. Several types of T cell subgroups can be activated by the 
antigens which are processed and presented by APCs, and each type of T cell is 
especially equipped to deal with each unique virulent factor associated with 
bacterial and/or viral pathogens. There are two main subsets of T cells, known as 
CD4+ and CD8+ T cells, that are distinguished by associated cell surface 
molecules. T cells that are positive for CD4 are also known as T helper cells, and 
this type of cell is considered as being the most prolific cytokine producers (Wang 
et al., 2008). This subset of T cells can be further subdivided into Th1 and Th2 
groups, and the cytokines they produce are known as Th1 and Th2 type 
cytokines. Th1 type cytokines induce pro-inflammatory responses and activate 
macrophages to induce the generation of cytotoxic T cells leading to a cell 
mediated immune response. Interferon gamma (IFN-γ) and tumor necrosis factor 
alpha (TNF-α) are the primary Th1 type cytokines (Vesosky et al., 2006). The 
Th2-type cytokines, including interleukins 4, 5, 10, and 13, are associated with 
anti-inflammatory responses and B cell activation leading to humoral immune 
responses. Moreover, Th2 cytokines are capable of counteracting and/or 
balancing Th1 cytokine mediated immune responses (Berger, 2000). CD8+ T 
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cells, which are also called cytotoxic T cells, are involved in killing cancer cells as 
well as cells infected by either virus or bacterial microbes. These cells express 
CD8+ glycoprotein and recognize their target by binding to antigen associated 
MHC class I molecules.  
When helper T cells recognize the antigen presented on the surface of the 
B cell, they become activated, which in turn activates the B cells (Parker, 1993). 
Activated individual T and B cells are thus selected to undergo clonal expansion 
in order to produce sufficient numbers of clones that differentiate into effector T 
and B cells, thereby removing pathogens via either cell or humoral mediated 
immune defenses (Braciale et al., 2012).  
Cell mediated immunity is an immune response that involves the 
activation of macrophages and natural killer cells, the production of antigen 
specific T cells, and the release of various cytokines in response to antigen 
stimulation. Cell mediated immunity is directed primarily against microbes that 
survive in phagocytes and microbes that infect non-phagocytic cells. On the other 
hand, for humoral or antibody mediated immunity, B cells differentiate into 
plasma cells that secrete specific antibodies. In mammals there are five types of 
antibodies: IgA, IgD, IgE, IgG, and IgM, each with different biological properties 
and capabilities to recognize different kinds of antigens. Based on those specific 
antibodies, each activated B cell can recognize a unique antigen and neutralize 
specific pathogens (Janeway, 2001). 
1.2 Inflammation 
Inflammation is the first response of the immune system to a wound or 
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infection and may then activate the innate immune cascade. It is characterized 
by redness, heat, swelling, pain and dysfunction of the involved site. The host 
reaction is protective as the purpose is to eliminate injurious stimuli (pathogens, 
damaged cells, or irritants), as well as to clean up dead and dying cells and 
initiate the healing process in the inflamed tissue site (Sadik et al., 2011). 
Although inflammation plays an important role in isolating the infected area, 
mobilizing effector cells, releasing molecules to the site and promoting healing, 
improperly regulated inflammation may lead to tissue damage and enhanced 
host disease. 
1.2.1 Acute Inflammation 
Inflammation may be classified into either acute or chronic in type, each 
with different features. Its principal signs, as detailed above, include pain and 
loss of function. It can be caused by mechanical trauma, chemical injuries or 
infection, all of which induce tissue injury. The injured tissue will then trigger an 
immediate, early and acute inflammatory response by releasing inflammatory 
mediators to nearby blood vessels. These mediators begin to function within a 
relatively short time period (minutes to hours) and induce increased blood flow 
(due to blood vessel dilation) accompanied by vascular endothelial cell swelling 
and retraction, both of which lead to increased vascular permeability (Ryan and 
Majno, 1977). Another function of these mediators is to chemoattract neutrophils 
to the infected tissue site. Circulating neutrophils first roll along the swollen 
vascular endothelial cell and adhere to these cells. This process is mediated by a 
family of molecules called selectins. Adjacent neutrophils adhere to each other, 
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aggregate and undergo shape changes. When emigration begins, the neutrophils 
actively migrate through the vessels into the damaged tissues (Armstrong et al., 
2004).  
1.2.2 Chronic Inflammation 
If the sequelae of acute inflammation are not resolved in a timely fashion, 
but rather persist, continuing tissue necrosis and damage occurs and acute 
inflammation may become more long term, or chronic. Moreover, some 
pathogens tend to directly induce chronic rather than acute inflammation. Many 
of the features of acute inflammation continue as the inflammation becomes 
chronic inflammation (lasting days to years), including increased blood flow and 
vascular permeability leading to leukocyte infiltration and tissue damage. During 
the period of chronic inflammation, an induced progressive shift of immune cell 
types (from neutrophils to macrophages) at the inflammation site will lead to 
simultaneous destruction and healing of the inflamed tissue with accompanying 
fibrosis and angiogenesis (Rieder et al., 2007). Macrophages, the primary cell 
type of chronic inflammation, are derived from monocytes and reach the injury 
site within 24-48 hours. These cells are activated to fulfill immunological and 
secretory functions, including phagocytosis of pathogens and cellular debris, 
while at the same time, releasing cytokines. The released cytokines activate 
lymphocytes and other immune cells in response to pathogen stimulation 
(Fujiwara and Kobayashi, 2005).  
Both acute and chronic inflammation are tightly regulated by coordinated 
functions of cytokines, chemokines, growth factors and several other processes. 
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Chemokines provide directional cues for movements of leukocytes which release 
cytokines at the inflammatory site to regulate the inflammatory process (Luster, 
1998).  For example, IL-33, a member of the IL-1 superfamily, signals through 
ST2 and reduces corneal inflammation through upregulation of Th2 type 
cytokines and anti-inflammatory cytokine production (Hazlett et al., 2010).  
1.2.3 Inflammatory Cells 
There are several types of cells involved in both acute and chronic 
inflammatory responses. Langerhans cells are dendritic cells which are localized 
at many mucosal sites. These cells play an important role in initiation of the 
immune response in bacterial, viral, and parasitic infection, particularly in the eye 
(Hazlett et al., 2002). In the skin, these epidermal dendritic cells also regulate 
immune reactions in both sterile inflammation and infectious disease (Seiffert et 
al., 2002). During infection, local Langerhans cells take up and process the 
invading microbial antigens to become fully activated APCs. Activated 
Langerhans cells are then capable of presenting processed antigens to T cells. 
Under normal conditions, the corneal epithelium is devoid of MHC class II 
positive Langerhans cells (Jager, 1992), but possesses its own bone marrow 
derived cells, including cornea epithelial Langerhans cells and anterior stroma 
dendritic cells, which can function as APC after antigen stimulation (Hamrah and 
Dana, 2007). Moreover, in the peripheral conjunctiva, resident Langerhans cells 
are present with antigen presenting capacity (Hazlett et al., 2002).  
Activated Langerhans cells may trigger an inflammatory response by 
releasing chemokines to chemoattract neutrophils which are the main cell type 
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participating in acute inflammatory processes (Tamarozzi et al., 2011). During the 
acute phase of inflammation, particularly after bacterial infection, neutrophils are 
one of the first-responders among inflammatory cells to infiltrate and accumulate 
at the inflammatory site. Since the lifespan of neutrophils is relative short 
(approximately 10 hours), they need to be replenished quickly by more infiltrating 
cells. Because the inflammatory mediators (such as histamine) released by 
damaged tissues increase the vessel permeability, the aggregated neutrophils 
emigrate from vessels into their target tissues down a concentration gradient of 
the chemotactic factors (Kobayashi, 2006). Neutrophil chemotactic factors 
include complement component (C5a), cytokines, chemokines and leukotriene 
B4 (LTB4) (Elner et al., 1990). Chemotactic mediators bind to surface receptors 
on neutrophils to induce calcium influx and, in turn trigger, assembly of 
cytoskeletal contractile elements which initiate neutrophil migration (Cronstein et 
al., 1990). As soon as migration to the target tissue is complete, neutrophils bind 
to what is recognized as abnormal (e.g., bacterial and virus particles) and extend 
pseudopodia to surround them. Pseudopodia then fuse to completely enclose 
these structures to form a cytoplasmic phagosome which fuses with neutrophilic 
granules. These granules discharge their contents which are exposed and lysed 
by lysosomal enzymes. If the particles are bacteria, neutrophils kill and destroy 
them by both oxidative and nonoxidative mechanisms. Important oxidative 
mechanisms involve the release of hydrogen peroxide generated by the NADPH 
oxidase system and hypochlorous acid generated by myeloperoxidase (Rosen, 
2004). Important nonoxidative molecules include anti-microbial peptides (e.g., 
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defensins), lysozyme, neutral serine proteases, and bactericidal/permeability 
increasing protein (BPI). Moreover, recent studies show that neutrophils are 
capable of killing bacteria extracellularly. Upon activation, neutrophils secret 
granule containing proteins and chromatins into the extracellular space and form 
extracellular fibers or neutrophil extracellular traps (NETs). These fibers bind to 
both Gram-positive and Gram-negative bacteria, degrading virulence factors, and 
killing the bacteria (Brinkmann et al., 2004).  
The primary cell type of chronic inflammation is the macrophage. 
Macrophages are derived by the differentiation of monocytes and participate in 
both innate and adaptive immune responses. Macrophages regulate the immune 
system through initiating and directing the immune response, including 
phagocytosis, antigen processing/presentation, cytokine production, generation 
of reactive oxygen species and nitric oxide release. When monocytes migrate to 
the injured tissue attracted by chemotactic factors, they will differentiate into 
macrophages. These recruited cells as well as macrophages at the tissue site 
(fixed macrophages), ingest the invading pathogen to form a phagosome which 
fuses with lysosomes within the macrophage cytoplasm. The fusion product, the 
phagolysosome, contains enzymes and toxic peroxides to digest and kill the 
pathogen. After processing the pathogen, the macrophage will integrate the 
antigen into the cell membrane and attach it to MHC class II molecules which 
present the antigen to helper T cells (Unanue, 1984). The digested microbial 
products, such as LPS, signal through PRRs (e.g., TLR4) or other surface 
receptors to stimulate and activate the macrophages to secret both pro- and anti- 
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inflammatory cytokines (Daniels et al., 2000). Unfortunately, sustained production 
of pro-inflammatory cytokines released by macrophages may induce chronic 
inflammation leading to increased tissue damage.  
1.3 Corneal Innervation 
The cornea is one of the most densely innervated tissues of the body 
(Muller et al., 2003). Corneal nerves, composed primarily of sensory nerve fibers, 
are found in many species, including the mouse (de Castro et al., 1998) and 
human (Al-Aqaba et al., 2010; McKenna and Lwigale, 2010). In addition, 
sympathetic (Marfurt and Ellis, 1993) 
and parasympathetic nerves (Marfurt 
et al., 1998), which respectively 
originate from the superior cervical 
and ciliary ganglia, contribute 
moderately to the innervation of the 
cornea. At the periphery, nerve 
bundles enter the cornea in a radial 
fashion parallel to the corneal surface and then subdivide into smaller side 
branches (Muller et al., 2003). These nerves are important not only for overall 
corneal health, particularly, for the epithelial cells they innervate (Baker et al., 
1993), but also are essential in neuroimmunoregulation of the tissue.  
Figure 1. Stromal nerves (human cornea) penetrate 
through Bowman's membrane in anterior-cornea 
whole mounts (a–c) and in a 30 μm-thick 
perpendicular section (d). (From Marfurt et al., 2010).
1.4 Neuroimmunoregulation 
Neuroimmunoregulation is the bidirectional communication between the 
neuroendocrine and immune systems (Weigent and Blalock, 1987). It is required 
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for immune system homeostasis and optimal host defense (Downing and Miyan, 
2000). Neuropeptides, small protein-like molecules, are used by neurons to 
communicate with each other, and as such, play an important role in these 
processes (Scharrer, 1987). Of these peptides, two, namely substance P (SP) 
and vasoactive intestinal peptide (VIP) are the main focus of ongoing studies in 
the laboratory. SP is a neuropeptide secreted by nerves and inflammatory cells 
and responsible for a pro-inflammatory type of response (O'Connor et al., 2004); 
whereas VIP is an anti-inflammatory neuropeptide that affects the immune 
response antithetically (Delgado et al., 2004).  
1.5 VIP 
Figure 2. VIP structure: protein and gene. A. sequence of 
VIP family peptides. B. VIP gene structure (Delgado et al., 
2004). 
 
VIP, a 28 amino acid 
neuropeptide (Figure 2), is a 
member of the secretin 
superfamily that includes 
secretin, growth hormone 
releasing peptide (GHRP) and 
pituitary adenylate cyclase 
activating peptide (PACAP) 
(Smalley et al., 2009). VIP is 
synthesized from a precursor molecule (prepro-VIP, 170 amino acids) which 
contains peptide histidine methionine (PHM; in human tissues) or peptide 
histidine isoleucine (PHI; its counterpart in other mammalian species) (Delgado 
et al., 2004). After cleavage by several types of signal peptidases (Bloom et al., 
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1983; Delgado et al., 2004; Itoh et al., 1983), VIP is delivered by neurons to 
immune organs and lymphoid tissues in the heart, gastrointestinal tract, lungs, 
and the kidney (Henning and Sawmiller, 2001). VIP is also detected ocularly in 
human aqueous humor (Koh et al., 2005), and corneal endothelium (Koh and 
Waschek, 2000) and also is present in both human and mouse corneal nerves 
(parasympathetic fibers) (Muller et al., 2003). VIPergic fibers have been identified 
in the normal corneal 
epithelium and show 
more immunostaining 
after infection in the 
stroma of BALB/c vs 
B6 mice (Szliter et al., 
2007).  
VIP functions by 
binding to one of three 
receptors to activate 
the following two 
pathways: one cAMP-
dependent and the 
other one cAMP-
independent, as are 
shown in Figure 3 
(Chorny et al., 2006). Two 
Figure 3. VIP signaling: cAMP dependent and independent 
pathways (Chorny et al., 2006).  
 
 - 13 -
VIP receptors are VIP-shared type 2 (VPAC1 and VPAC2) receptors (Jamen et 
al., 2000) and a third one is a PACAP-preferring type 1 (PAC1) which shows 
lower affinity for VIP (Laburthe and Couvineau, 2002). These VIP receptors are 
type II, G protein coupled receptors (GPCR), which are detected in several types 
of immune cells (Cocco et al., 2010), and can trigger a cascade of intracellular 
events that differ depending on cell and receptor types. Both VPAC1 and VPAC2 
mRNA are detected preferentially in CD4+, but also in CD8+ T cells purified from 
mouse spleen; however, no signal is detected in either unstimulated or LPS-
stimulated B cells (Delgado et al., 1996). VPAC1 is also constitutively expressed 
in resting CD4+ and CD8+ T cells purified from human peripheral blood (Lara-
Marquez et al., 2001). In the mouse, BALB/c mouse-derived 
macrophages display significantly higher VIPR1 (VPAC1) mRNA levels when 
compared with cells from B6 mice in both unstimulated and LPS-stimulated cells, 
suggesting that the effects of VIP are mainly mediated via VIPR1 on 
macrophages (Szliter et al., 2007).  
The interaction between VIP and its receptors induces a wide variety of 
biological activities. Among these, VIP displays several non-immune activities, 
which include: systemic vasodilatation, bronchodilatation, smooth muscle 
relaxation and neurotrophic effects (Delgado et al., 2004). VIP also accelerates 
wound healing processes in mechanically-induced damage of human bronchial 
epithelial cells (Guan et al., 2006), and protects cold-restraint stress-induced 
gastric lesions and mast cell degranulation (Tuncel et al., 1998). Importantly, VIP 
has been considered in itself to be a growth factor functioning during mouse 
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embryonic development (Gressens et al., 1993; Gressens et al., 1997). 
The immunological actions of VIP are primarily anti-inflammatory effects in 
nature (Smalley et al., 2009). Such effects include: inhibition of pro-inflammatory 
cytokine production and T cell proliferation (Ganea, 1996), inhibition of 
macrophage chemotaxis and phagocytic activity (De la Fuente et al., 1996) and 
inhibition of free radical production (Gonzalez-Rey et al., 2007). VIP can promote 
generation of memory Th2 type T cells (Delgado et al., 2002) and can modulate T 
cell function in mice, shifting a Th1 to a Th2 type cytokine response (Gutierrez-
Canas et al., 2008). In various diseases, VIP reduces production of inflammatory 
cytokines (TNF-α, IL-12, IL-6, and IL-1β) while stimulating anti-inflammatory 
cytokines such as IL-10 and IL-1Ra production (Delgado and Ganea, 2008). 
Most notable to the current dissertation is that previous studies from this 
laboratory showed that after corneal infection with Pseudomonas aeruginosa (P. 
aeruginosa), exogenous synthetic VIP treatment significantly ameliorated 
disease and prevented corneal perforation by inhibiting pro-inflammatory 
cytokines (IFN-γ, IL-1β, TNF-α, and MIP-2), while stimulating anti-inflammatory 
cytokine (TGF-β1 and IL-10) production (Szliter et al., 2007).  
1.6 Growth Factors 
Growth factors are putatively involved in many biological activities such as 
cell growth, proliferation, differentiation, oncogenesis, and wound healing (Turner 
and Grose, 2010). Classical growth factors include: epidermal growth factor 
(EGF), keratinocyte growth factor (KGF also known as fibroblast growth factor-7, 
FGF-7), hepatocyte growth factor (HGF) and vascular endothelial growth factor 
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(VEGF).  
EGF functions through receptor dependent signaling and is well known for 
its multifaceted actions in development and maintenance of tissue homoeostasis 
(Lu and Kang, 2010). Amongst its functions, EGF stimulates epithelial growth and 
differentiation (Cohen, 1962) and enhances wound healing (Brown et al., 1989). 
EGF is also involved in the regulation of inflammation. As an example, during 
infection with an enteropathogenic strain of Escherichia (E.) coli, oral 
administration of EGF significantly reduced E. coli colonization (Buret et al., 
1998). EGF also accelerates corneal epithelial wound healing both in vivo and in 
vitro and corneal re-epithelialization in an organ culture wound model (Lu et al., 
2001). KGF, or FGF-7, binds to FGFR2 (Rotolo et al., 2008) and is a homeostatic 
factor with the potential for epithelial protection and repair after various insults 
(Finch and Rubin, 2004). KGF is also considered as a cytokine which mediates 
mesenchymal-epithelial interactions (Rubin et al., 1995). Regarding its role in 
infection, intratracheal treatment with KGF increased clearance of P. aeruginosa 
in an induced lung injury bacterial infection model (Viget et al., 2000), implying its 
efficacy as an anti-bacterial agent. HGF, which binds to c-met receptor (Bottaro et 
al., 1991), is a multifunctional polypeptide which regulates diverse cellular 
processes, including cell survival, proliferation, migration, and differentiation (Liu, 
2004). HGF has also been shown to have an anti-inflammatory effect due to its 
ability to block NF-κB signal pathway transduction and E-selectin expression in 
human umbilical vein endothelial cells (Gong et al., 2006). Interestingly, the 
injured cornea releases IL-1 from epithelial cells to induce production of both 
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HGF and KGF in keratocytes (Suzuki et al., 2003), suggesting a potential 
beneficial effect of HGF and KGF in corneal wound healing. Another type of 
growth factor, VEGF (VEGF-A), as a classical growth factor, can influence cell 
proliferation, migration and survival (Penn et al., 2008), but it also can signal 
through its receptors VEGFR1 and VEGFR2 to control vasculogenesis (Rini and 
Small, 2005; Shibuya and Claesson-Welsh, 2006). In general, binding of VEGF-A 
to VEGFR1 has anti-angiogenic effects by negative regulation of VEGFR2. If 
levels of VEGFR2 are reduced by an antagonist (Tille et al., 2001) or in VEGFR2 
knock out mouse embryos (Nicosia, 1998), reduced or lack of VEGFR2 inhibits 
VEGF induced vascular angiogenic effects. It has been shown that VIP increases 
VEGF (Valdehita et al., 2007) expression and secretion in human cancer cells 
and nerve growth factor (NGF) expression (Hill et al., 2002) in mouse embryonic 
neural tube. 
1.7 TLRs  
TLRs, the best characterized class of PRRs (Janeway and Medzhitov, 
1998), play an important role in pathogen recognition and activation of innate 
immunity, which may lead to activation of adaptive immunity (Medzhitov and 
Janeway, 2000). Thirteen TLRs are present in humans and mice with the 
exception that TLR10 is only present in humans and TLRs 11, 12 and 13 are only 
expressed in mice (Beutler, 2004). TLRs are expressed in a variety of ocular 
tissues, including cornea, and several other tissues, such as the retina. For 
example, after infection with P. aeruginosa, TLR4 is expressed in the corneal 
epithelium and stroma (Jiang el al., 2012) and its expression is significantly 
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increased when compared to the normal, uninfected cornea (Huang et al., 
2006a).  
 
Table 1. Toll-like receptors, ligands and adaptor molecules (Gomariz et al., 2007). 
TLRs differ from each other in ligand specificities, expression patterns, 
and target genes (Dowling et al., 2008). These receptors recognize highly 
conserved PAMPs, including bacterial cell-surface LPS, lipoproteins, flagellin, 
double-stranded RNA of viruses or the unmethylated CpG islands of bacterial 
and viral DNA. In addition, TLR recognition is ligand specific, as summarized in 
Table 1.  
Based on their functions, TLRs can be divided into pro-inflammatory and 
anti-inflammatory types. Pro-inflammatory TLRs function predominately as 
homodimers, with some exceptions, as is the case for TLR1, TLR2 and TLR6. 
TLRs also require co-receptors for optimal ligand sensitivity. For example TLR4 
requires myeloid differentiation protein 2 (MD-2) to recognize LPS (Chaudhuri et 
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al., 2005). Moreover, the delivery of LPS to MD-2 can be facilitated by CD14 and 
LPS binding protein (LBP) (Kumar and Yu, 2006). Upon activation, adaptor 
molecules, such as MyD88, TIRAP (also called MAL), TRIF and TRAM, are 
recruited by TLR for signal amplification. TLRs can also amplify their signals by a 
MyD88-independent pathway which requires TRIF, TBK1 and IRF3 to amplify 
signaling (Takeda and Akira, 2004). These proteins activate downstream 
molecules within the cell leading to NF-κB activation and consequently, induction 
of genes that regulate the inflammatory response (Zhang and Ghosh, 2001). 
TLRs also are involved in regulation of anti-inflammatory responses. In this 
regard, the negative regulators of TLR signaling, including single Ig IL-1R-related 
molecule (SIGIRR) and ST2, have been identified and characterized. SIGIRR 
and ST2 sequester the recruitment of adaptor molecules including MyD88 and 
IL-1 receptor-associated kinase (Sweet et al., 2001). They also inhibit the 
formation of pro-inflammatory TLR signaling complexes and regulate pro-
inflammatory cytokine and chemokine production (O'Neill, 2003).   
TLR signaling is tightly regulated, since prolonged or excessive activation 
of TLRs may lead to uncontrolled inflammation in the host (Shibolet and Podolsky, 
2007). In this regard, in a recent study from this laboratory, murine beta-defensin-
2 (mBD2) was found to negatively regulate TLR2, TLR4 and TLR9 signaling, and 
promoted the resistance response to corneal infection with P. aeruginosa (Wu et 
al., 2009a). Other studies showed that numerous proteins, such as IL-1R-
associated kinase M (IRAK-M), A20 and Tollip, also negatively regulate TLR 
signaling (Whitmore et al., 2007). Interestingly, in other studies, intraperitoneal 
 
 - 19 -
administration of VIP (1 nM) down-regulated TLR-2 and TLR-4 expression in 
colonic extracts in a model of Crohn’s disease and TLR-4 expression on the 
surface of macrophages, dendritic cells and lymphocytes within the mesenteric 
lymph nodes (Gomariz et al., 2005).  
1.6 Overview and Significance 
In the United States, microbial keratitis is the most frequent complication 
for extended wear contact lens users. Its incidence among this group is 25,000-
30,000 cases each year, with treatment estimated at between $15 and $30 
million, an extensive medical and economic impact (Khatri et al., 2002). P. 
aeruginosa, a common Gram-negative bacteria associated with microbial 
keratitis, accounts for approximately 70% of the culture-proven cases in contact 
lens users (Schein et al., 1989).  
P. aeruginosa is an opportunistic pathogen that produces 
lipopolysaccharide (LPS/endotoxin) and numerous other virulence factors, 
including but not limited to bacterial toxins which contribute to the progression of 
microbial keratitis (Hazlett, 2004). However, the prognosis of the disease also is 
influenced by host immunity, the inflammatory response, and successful 
treatment with antibiotics (Hazlett, 2004). Clinically, the disease progresses 
rapidly and is characterized by a suppurative stromal infiltrate, inflammatory 
epithelial edema, ocular pain and redness, stromal ulceration, decreased vision, 
and oftentimes, corneal perforation (Hazlett, 2007).  
In order to better understand disease pathogenesis, animal models of P. 
aeruginosa-induced corneal infection have been established and include topical 
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application of the bacteria after wounding, intrastromal inoculation, or placement 
of a contaminated contact lens or suture on the cornea (Hazlett LD, 2004). Of 
particular interest for the current studies is the defined inbred murine model of P. 
aeruginosa-induced corneal infection. C57BL/6 (B6) mice are Th1 responsive to 
P. aeruginosa infection and are classified as susceptible, since the cornea 
perforates at 5-7 days post infection (p.i.) (Hazlett et al., 2000). In contrast, 
BALB/c mice are Th2 responsive to P. aeruginosa infection and are classified as 
resistant, since less destruction of the stroma occurs and the cornea does not 
perforate at 5-7 days p.i. (Hazlett et al., 2000). Furthermore, a recent study from 
this laboratory has found that VIP balances Th1/Th2 type cytokine levels, leading 
to protection against corneal perforation in susceptible B6 mice (Szliter et al., 
2007).  
      
Figure 4. Slit lamp photographs of  
mouse eyes infected with P. 
aeruginosa at 7 days p.i. A, B6, 
susceptible strain; B, BALB/c, 
resistant strain. 
 
In this regard, the goal of the current dissertation is to test the following 
hypotheses: 
1. VIP modulates growth factor expression in microbial keratitis. 
2. VIP regulates TLR signaling pathways in microbial keratitis. 
3. VIP is not required for growth factors and their receptor expression in 
the normal cornea, but critical for their regulation in the infected cornea. 
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Chapter 2 
VIP AND GROWTH FACTORS IN THE INFECTED CORNEA 
2.1 Abstract 
Purpose. VIP is an anti-inflammatory neuropeptide that down-regulates 
pro-inflammatory cytokines and promotes healing in a susceptible model of P. 
aeruginosa keratitis. Growth factors also play a role in corneal healing and 
restoration of tissue homeostasis after wounding. However, whether VIP 
treatment modulates growth factors to promote healing in the infected cornea 
remains untested and is the purpose of this study. Methods. B6 mice were 
injected with VIP and mRNA and protein levels, and immunostaining for EGF, 
FGF, HGF, and VEGF-A were done. Exogenous treatment with a mixture of the 
growth factors also was tested and levels of cytokines, defensins, and bacterial 
counts were determined. Results. Real-time RT-PCR, immunostaining, and 
ELISA data demonstrated that treatment with VIP enhanced levels of EGF, FGF, 
and HGF during disease, and that VEGF-A, and associated angiogenic 
molecules also were increased by VIP. Moreover, immunohistochemical studies 
confirmed that both epithelial and stromal cells participated in growth factor 
production. Most notably, treatment with a mixture of EGF, FGF, and HGF after 
disease onset, prevented corneal perforation when compared with controls. This 
outcome was associated with down-regulation of pro-inflammatory cytokines 
such as macrophage inflammatory protein-2 (MIP-2), up-regulation of anti-
inflammatory cytokines such as TGF-β, and antimicrobials β-defensins 2 and 3, 
as well as decreased plate counts at 1 day postinfection (p.i.) (p = 0.0001). 
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Conclusions. Collectively, the data provide evidence that VIP treatment 
modulates growth factors, angiogenic molecules, and defensins in the infected 
cornea and that this in turn promotes healing and restoration of tissue 
homeostasis. 
2.2 Introduction 
An opportunistic, gram-negative pathogen, P. aeruginosa is one of the 
most virulent organisms associated with microbial keratitis and is often 
associated with contact lens usage (Wilhelmus, 1987).  Both bacterial (e.g., 
lipopolysaccharide) and host factors released from infiltrating cells during 
infection are thought to contribute to a rapidly progressing liquefactive stromal 
necrosis (Iglewski et al., 1977; Kernacki et al., 2000; Moon et al., 1988; Pillar and 
Hobden, 2002). Experimental murine models of the disease have been 
established: Th1 responder mouse strains (e.g., B6) are susceptible (cornea 
perforates), whereas Th2 responder strains (e.g., BALB/c) are resistant (cornea 
heals) (Hazlett et al., 2000). 
In previous studies using these murine models, we provided evidence that 
an anti-inflammatory neuropeptide, VIP given exogenously, promotes resistance 
against P. aeruginosa corneal infection by regulation of cytokine production and 
subsequent alteration of the host inflammatory cell response (Szliter et al., 2007). 
Neuropeptides, such as VIP are small protein-like molecules used by neurons to 
bidirectionally communicate with the cells of the immune system (Weigent and 
Blalock, 1987). In the eye, VIP can be detected in corneal nerves and the 
aqueous humor in both mice and humans (Delgado et al., 2004). Others also 
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have shown previously that VIP reduces pro-inflammatory cytokine production, 
limits cell-mediated immunity, and inhibits macrophage and T cell proliferation 
(Delgado et al., 2004); and by down-regulation of IL-6 and TNF-α, the 
neuropeptide showed a protective effect in models of endotoxemia (Delgado et 
al., 1999a). Despite these anti-inflammatory effects which have been reported in 
diverse systems and which clearly modulate disease outcome, the role of VIP in 
regulation of corneal healing, specifically, control of growth factor production, has 
not been examined. 
Classically, growth factors, which also may be considered as cytokines, 
bind to their receptors and regulate cell growth, proliferation, migration, and 
differentiation (Turner and Grose, 2010). Thus, the current studies investigated 
the potential regulation by VIP of growth factors in P. aeruginosa-infected 
corneas in B6 (susceptible) mice that exhibit lower levels of VIP when compared 
with resistant (BALB/c) mice (Hazlett et al., 2000). Exogenous VIP treatment was 
given to B6 mice to determine whether VIP modulates growth factor production 
and thereby, favors resolution of disease. Data from these studies provide 
evidence that VIP treatment leads to up-regulation of growth factor production in 
the cornea after P. aeruginosa infection, and that both epithelial and stromal cells 
are participatory. Furthermore, evidence is provided to show that treatment with a 
mixture of growth factors, given topically after infection, prevents perforation of 
the cornea. Mechanistically this is achieved by down-regulation of pro-
inflammatory cytokines, up-regulation of anti-inflammatory cytokines, 
antimicrobials β-defensins 2 and 3, and decreased bacterial plate counts. The 
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data suggest that VIP modulates growth factor production in the infected cornea 
and that this in turn, contributes to better disease outcome. 
2.3 Materials and Methods 
Infection 
Eight-week-old female B6 mice (The Jackson Laboratory, Bar Harbor, ME) 
were anesthetized with ethyl ether and placed beneath a stereoscopic 
microscope at ×40 magnification. The cornea of the left eye was wounded 
(Rudner et al., 2000) and a 5-μL aliquot containing 1.0 × 106 CFU/μL of P. 
aeruginosa (American Type Culture Collection, strain 19,660, Manassas, VA) 
was topically delivered. Animals were treated humanely and in compliance with 
the Association for Research in Vision and Ophthalmology Statement on the Use 
of Animals in Ophthalmic and Vision Research. 
Ocular Response to Bacterial Infection 
Corneal disease was graded (Hazlett et al., 1987): 0 = clear or slight 
opacity, partially or fully covering the pupil; +1 = slight opacity, fully covering the 
anterior segment; +2 = dense opacity, partially or fully covering the pupil; +3 = 
dense opacity, covering the entire anterior segment; and +4 = corneal perforation 
or phthisis. After infection, a clinical score was recorded (days 1, 3, 5, and/or 7) 
for each mouse (n = 5 per group per treatment for two experiments = 20 mice). 
VIP Treatment 
In vivo treatment with synthetic VIP (Bachem, Torrance, CA) has been 
described previously (Szliter et al., 2007). In brief, B6 mice received daily IP 
injections of VIP (5 nM in 100 μL sterile phosphate buffered saline, PBS) at 1 day 
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before infection (Day = −1) through a maximum of 7 days p.i. Control mice were 
injected similarly with sterile PBS (100 μL). 
Real-time RT-PCR 
Total RNA was isolated from an individual cornea of PBS, VIP, or growth 
factor-treated mice (n = 5 per group per time per treatment for two experiments = 
140 mice) using RNA-Stat 60 (TelTest, Friendswood, TX), per the manufacturer's 
recommendations and quantitated spectrophotometrically (260 nM). One 
microgram of total RNA was reverse transcribed using Moloney murine leukemia 
virus (MMLV) reverse transcriptase. The 20-μL reaction mixture contained 200 U 
of MMLV-reverse transcriptase, 10 U of RNasin, 500 ng of oligo (dT) primers, 10 
mM dNTPs, 100 mM DTT, and MMLV reaction buffer (Invitrogen, Carlsbad, CA). 
After, cDNA was amplified using SYBR Green Master Mix (SABiosciences, 
Frederick, MD), per the manufacture's recommendation. Briefly, the 20-μL 
reaction system contained 10 μL of SYBR Green PCR Master Mix, 1.0 μL of 10-
μM primer mix, 2 μL of cDNA (diluted 1/10), and diethyl pyrocarbonate water. All 
primers were purchased from SABiosciences, except for β-actin which was 
designed using PrimerQuest (Integrated DNA Technologies, Cambridge, MA) 
whose forward primer is 5’-GAT TAC TGC TCT GGC TCC TAG C-3’; the reverse 
primer is 5’-GAC TCA TCG TAC TCC TGC TTG C-3’. The primer sequences for 
MIP-2, TNF-α, TGF-β (Szliter et al., 2007) and β-defensins-2 and 3 (Wu et al., 
2009a; Wu et al., 2009b) were provided previously. 
Quantitative real-time RT-PCR reactions were performed (MyiQ single 
color real-time RT-PCR detection system; Bio-Rad, Hercules, CA). Optimal 
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conditions for PCR amplification of cDNA were established using routine 
methods (Heid et al., 1996). Relative mRNA levels were calculated after 
normalization to β-actin. 
Immunofluorescent Staining 
Normal, uninfected, and infected eyes were enucleated from VIP, PBS, 
and growth factor-treated B6 mice (n = 5 per group per time for two experiments 
= 60 mice) at 1 and 5 days p.i. Tissue was immersed in 1X Dulbecco's PBS 
(Mediatech, Inc., Herndon, VA), embedded (Tissue-Tek OCT compound; Miles, 
Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer thick sections were cut, 
mounted to polylysine-coated glass slides, and incubated in a moist chamber at 
37°C overnight. After a 2-minute fixation in acetone, nonspecific staining was 
blocked with 10 mM sodium phosphate buffer containing 2.5% bovine serum 
albumin and donkey IgG (1:100) for 30 minutes at room temperature. For 
immunostaining, sections were incubated for 1 hour each with goat anti-mouse 
VEGF-A, EGF and/or HGF (R&D, Minneapolis, MN), goat anti-human FGF-7 
(Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-mouse β-defensin 2 (1:50, 
Santa Cruz) or rabbit anti-mouse β-defensin 3 (1:50, Santa Cruz), followed by a 
secondary Ab, Alexa Fluor 594 conjugated donkey anti-goat (1:1500, Invitrogen, 
Eugene, OR) or Alexa Fluor 594 conjugated donkey anti-rabbit Ab (1:1500, 
Invitrogen; both = red color). Sections were then incubated for 2 minutes with 
nuclear acid stain (1:20,000, SYTOX Green; Lonza, Walkersville, MD). Controls 
were similarly treated, but the primary Ab was replaced with the same host IgG. 
Finally, sections were visualized and digital images captured with a confocal laser 
 
 - 27 -
scanning microscope (Leica TCS SP2; Leica Microsystems, Bannockburn, IL). 
ELISA 
Growth factor protein levels were tested using ELISA kits (R&D). Corneas 
from PBS and VIP-treated B6 mice were individually collected (n = 5 per group 
per time per treatment for two experiments = 100 mice) at 1, 5, and 7 days p.i. 
Corneas were homogenized in 0.5 mL of PBS with 0.1% Tween 20. All samples 
were centrifuged at 13,000 rpm for 5 minutes and an aliquot of each supernatant 
was assayed in duplicate for EGF, KGF/FGF-7 (FGF), HGF, and VEGF-A per the 
manufacturer's instruction. ELISA also was used to test for receptor protein levels 
for VEGFR1 and VEGFR2. The reported sensitivity of these assays is <0.95 
pg/mL for EGF, <156.25 pg/mL for HGF, 15.62 pg/mL for KGF/FGF-7 (FGF), <3.0 
pg/mL for VEGF-A, <9.8 pg/mL for VEGFR1, and <27 ng/mL for VEGFR2. 
Growth Factor Treatment 
Recombinant mouse EGF, KGF/FGF-7 (FGF) and HGF (all from R&D) 
were dissolved in PBS to a final concentration of either 40 μg/mL (EGF and HGF) 
or 20 μg/mL (FGF). After mice were infected, 5 μL of a mixture of the three 
growth factors (2 μL EGF, 0.4 μL FGF, and 2 μL HGF in 0.6 μL PBS) was 
delivered topically, once on the day of infection, twice at 1 day p.i. and once daily 
through 4 days p.i. Concentrations for the growth factors were selected and 
modified after review of the literature (Baldwin and Marshall, 2002; Forster et al., 
2008; Fredj-Reygrobellet et al., 1987). Controls received PBS similarly. 
Bacterial Plate Counts 
Corneas from PBS or growth factor-treated B6 mice were collected (n = 5 
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per group per time for two experiments = 60 mice) at 1, 3, and 5 days p.i. and the 
number of viable bacteria were quantitated. Individual corneas were 
homogenized in sterile water containing 0.85% (wt/vol) NaCl containing 0.25% 
BSA. Serial 10-fold dilutions of the samples were plated on Pseudomonas 
isolation agar (Difco Laboratories, Sparks, MD) in triplicate and plates were 
incubated overnight at 37°C and bacteria counted. Results are reported as log10 
number of CFU per cornea ± SEM. 
Statistics 
The difference in clinical score between the two groups at each time point 
was tested by the Mann-Whitney U test. An unpaired, two-tailed Student's t-test 
was used to determine significance of all other data. For each test, differences 
were considered significant at P < 0.05 and represented as mean ± SD. Each 
experiment was performed twice for reproducibility and representative data from 
a typical experiment are shown. 
2.4 Results 
mRNA Expression of Growth Factors 
Whether VIP modulated mRNA expression patterns for selected growth 
factors was first assessed. The mRNA expression patterns of EGF, FGF, HGF, 
and EGF receptor (EGFR) are shown in Figures 5A, 5C, 5E, and 5G. Compared 
with PBS, treatment with VIP significantly increased EGF (Fig. 5A) mRNA 
expression in normal and infected cornea at 3 days p.i. (P < 0.05 and P < 0.001). 
FGF mRNA expression (Fig. 5C) was not significantly different between groups at 
all times tested. HGF mRNA expression (Fig. 5E) was significantly up-regulated 
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by VIP in normal, uninfected, and infected corneas at 1 and 3 days p.i. (P < 0.01, 
P < 0.05, and P < 0.01). EGFR was significantly increased at days 5 and 7 p.i. (P 
< 0.01 for both). There were no significant differences between the two groups for 
any of the growth factors at other time points tested (Figs. 5A, 5C, 5E, 5G). 
ELISA 
Protein expression patterns for the three growth factors were assessed 
after examination of mRNA expression patterns. Protein expression for EGF, FGF, 
and HGF also is shown in Figures 5B, 5D, and 5F. When compared with PBS, 
VIP treatment upregulated EGF protein expression (Fig. 5B) later in disease (5 
and 7 days p.i.; P < 0.01 and P < 0.01). Before infection and at 1 day p.i., levels 
were higher in the PBS treated group (P < 0.001 and P < 0.001). VIP treatment 
enhanced protein levels of FGF (Fig. 5D) only at 7 days p.i. (P < 0.05). For HGF 
(Fig. 5F), VIP significantly increased protein expression at 1 and 5 days p.i. (P < 
0.05 and P < 0.01) and remained elevated at 7 days p.i., but was not significant. 
mRNA Expression of Angiogenic Molecules 
Whether mRNA expression of angiogenic molecules were changed after 
VIP also was assessed. For VEGF-A (Fig. 6A), treatment with VIP versus PBS 
significantly increased mRNA levels only in the normal, uninfected cornea (P < 
0.001); but no difference between the two groups was seen at either 1 or 5 days 
p.i. For VEGFR1 (Fig. 6C), VIP increased mRNA expression in normal, 
uninfected cornea (P < 0.001), did not differ between groups at 1 day, but 
decreased levels at 5 (P < 0.01) days p.i. VIP increased VEGFR2 mRNA 
expression (Fig. 6E) in normal, uninfected (P < 0.05) cornea but no differences 
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were seen between groups at 1 or 5 days p.i. 
ELISA Analysis 
Protein expression patterns for angiogenic molecules were assessed after 
VIP treatment and compared with controls. VIP versus PBS significantly 
increased VEGF-A (Fig. 6B) protein expression in the infected cornea at 7 days 
p.i. (P < 0.05). VEGFR1 (Fig. 6D) was not significantly different between groups 
at all times tested. VEGFR2 protein levels (Fig. 6F) were significantly increased 
(more than two-fold) by VIP versus PBS at 7 days p.i. (P < 0.001). No differences 
in protein levels were detected between the two groups at the other times tested 
(Figs. 6B, 6D, 6F). Consistent with these data (Figs. 6G, 6H), a photograph taken 
with a slit lamp at 7 days p.i., shows greater vascularity in the peripheral cornea 
of VIP- (Fig. 6H) versus PBS- (Fig. 6G) treated mice. 
Immunostaining 
Immunohistochemistry was used to allow us to spatially localize EGF, FGF, 
HGF, and VEGF-A in the corneas of VIP- versus PBS-treated B6 mice at 1 (Figs. 
7A–J) and 5 days p.i. (Figs. 8A–J). At 1 day p.i. slightly increased 
immunostaining was seen for EGF after PBS versus VIP treatment (Figs. 7A, 7B, 
and insets) in the epithelium and stroma. For FGF, staining was similar between 
groups and in the epithelium (Figs. 7C, 7D). For HGF, VIP-enhanced stromal 
immunostaining, while more epithelial staining was seen in the PBS group (Figs. 
7E, 7F), VEGF-A staining was similar between groups and seen in both the 
epithelium and stroma (Figs. 7G, 7H, and insets). Negative controls (primary 
antibody substituted with species-specific IgG) showed no positive 
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immunostaining for each factor tested. An example of these negative controls 
shows lack of positive immunostaining (Figs. 7I, 7J) seen with each of the factors 
tested. 
At 5 days p.i., EGF (Figs. 8A, 8B), FGF (Figs. 8C, 8D), HGF (Figs. 8E, 8F), 
and VEGF-A (Figs. 8G, 8H) staining of increased intensity was detected in the 
epithelium and stroma of VIP- versus PBS-treated mice. Negative controls 
(primary antibody substituted with species-specific IgG) showed no positive 
immunostaining for EGF, FGF, or VEGF-A staining at either time point tested for 
either treatment. An example of these negative controls shows typical lack of 
positive immunostaining seen with each of the factors tested (Figs. 8I, 8J). 
Growth Factor Treatment 
Because results suggested that VIP exerted some of its healing effects in 
the infected cornea via modulation (enhancing) of growth factor production, the 
next study was performed to test that hypothesis. To assess whether the healing 
effects of VIP were through growth factor modulation, a mixture of EGF, FGF, and 
HGF was topically applied after infection. Clinical score data (Figure 9A) and 
photography with a slit lamp (Figs. 9B, 9C) revealed significantly less disease in 
the growth factor-treated mice at 5 days p.i. (P < 0.05 for clinical score). Although 
most corneas of growth factor-treated mice exhibited a +3 opacity, (only one 
perforated) all corneas of PBS-treated mice had perforated at 5 days p.i. In 
addition, RT-PCR analysis of growth factor- versus PBS-treated corneas showed 
that mRNA levels of the pro-inflammatory cytokine, MIP-2 (Fig. 9D), were 
significantly decreased (P < 0.05), while TGF-β (Fig. 9F; P < 0.001), VEGF-A (Fig. 
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9G; P < 0.001), and β-defensins 2 (Fig. 9H; P < 0.05) and 3 (Fig. 9I; P < 0.001) 
all were up-regulated. There was no difference between the two treatment groups 
for TNF-α (Fig. 9E), or for VEGFR1 or VEGFR2 (data not shown). 
Immunostaining 
To begin to determine the mechanism by which growth factors given 
topically contributed to corneal defense, we used immunohistochemistry to 
examine infected corneas for antimicrobial molecules which had been shown by 
this laboratory to be protective in the infected cornea (Wu et al., 2009a; Wu et al., 
2009b). Staining for antimicrobial β-defensins in the cornea is shown in Figures 
10A–F. After growth factor versus PBS treatment, increased immunostaining for 
mBD2 was detected in both the epithelium and stroma at 5 days p.i. (Figs. 10A, 
10B). However, negligible staining for mBD3 was observed, with no difference 
between groups (Figs. 10C, 10D). Controls (primary Ab substituted with species-
specific IgG) showed no positive immunostaining for mBD2 or mBD3. These 
negative controls showed lack of positive immunostaining and appeared similar 
to staining with nuclear label (SYTOX Green; Lonza; Figs. 10E, 10F). 
Bacterial Counts 
To determine whether increased β-defensin production correlated with 
decreased bacterial number in the cornea, bacterial plate counts (Fig. 10G) were 
used to detect viable bacteria in the infected cornea of mice treated with growth 
factors versus PBS at 1, 3, and 5 days p.i. When compared with controls, growth 
factor treatment led to decreased bacterial plate counts at 1 (P = 0.0001), 3 (P = 
0.35), and 5 days p.i. (P = 0.09), but was not significant at either of the latter 
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times. 
2.5 Discussion 
Previously, this laboratory has provided evidence that VIP, a 28-amino 
acid, anti-inflammatory neuropeptide, regulates cytokine production in P. 
aeruginosa-induced keratitis, leading to decreased stromal destruction in a B6 
mouse model in which the infected cornea normally perforates (Szliter et al., 
2007). In this regard, VIP is involved in the regulation of a wide variety of immune 
reactions and among its numerous anti-inflammatory functions, participates in the 
maintenance of immune homeostasis (Delgado et al., 2004). In addition, VIP has 
been considered in itself to be a growth factor (Gressens et al., 1997), whereas 
other studies have suggested that it does not function independently, but that it 
may regulate other more classic growth factors such as VEGF (Valdehita et al., 
2007) and NGF (Hill et al., 2002). These growth factors can facilitate 
noninfectious wound healing and may also function as anti-inflammatory 
cytokines. 
The present study indicates that VIP promotes production of EGF, FGF, 
HGF, and VEGF-A and participates in regulating angiogenesis, all of which 
contribute to resistance to P. aeruginosa keratitis. It is highly likely that these 
intriguing effects may be indirect, through facilitating wound healing, and/or 
epithelial barrier function, for example. It also is possible that the effect of VIP 
and growth factors may modulate inflammation, balancing its required 
contribution to the healing process, with its down-regulation which is permissive 
to healing. In this regard, the present study has shown that both epithelial and 
 
 - 34 -
stromal cells participate in growth factor production and are modulated by VIP 
treatment. Unfortunately, there is a dearth of other studies concerning the role of 
VIP regulating many of the classic growth factors which have been studied herein; 
thus, the effects of VIP on EGF, HGF, and FGF production are initially 
characterized in the present study. Despite this, previous investigators have 
shown that VIP can directly activate the EGFR (Bertelsen et al., 2004) which is 
confirmed at the mRNA level in the present study described herein. In addition, 
we found that VIP increases EGF expression at the mRNA and protein levels and 
by immunostaining at mid-to-later times p.i. However, early after infection, EGF 
mRNA levels were similar between the two groups, but unexpectedly, protein and 
immunostaining was slightly increased in the PBS- versus VIP-treated group 
initially, suggesting that VIP has a complex regulatory function for this growth 
factor. In addition, investigators reported that either EGF or VIP inhibited the 
secretion of several pro-inflammatory cytokines, such as IL-1 and IL-8, and also 
reduced adhesion of neutrophilic leukocytes to bronchial epithelial cells in vitro 
(Zhang et al., 2006). We reported previously that VIP significantly reduced pro-
inflammatory cytokine production in microbial keratitis, including IL-1 and MIP-2 
(murine homolog of IL-8) levels (Szliter et al., 2007), but the present study shows 
that this effect may have been enhanced indirectly through VIP modulation of 
EGF. In fact, in another study it was reported that during infection with an 
enteropathogenic strain of Escherichia coli oral administration of EGF 
significantly reduced E. coli colonization (Buret et al., 1998). These findings are 
consistent with a past study which has shown that VIP reduces P. aeruginosa 
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corneal bacterial load and with the present study which suggests that this effect 
may have been at least in part, due to up-regulation of EGF at later times p.i. via 
VIP administration. 
Another growth factor, KGF/FGF-7 also participates in disease resolution 
through reduction of bacterial load. In this regard, clearance of P. aeruginosa was 
increased by intratracheal treatment with KGF in an induced lung injury bacterial 
infection model (Viget et al., 2000). KGF also increased antimicrobials β-defensin 
2 and cathelicidin (LL-37) mRNA levels which were associated with reduced 
bacterial load in P. aeruginosa infection in a skin model (Erdag et al., 2004). 
These data are consistent with the present study, in that VIP increased FGF 
(KGF/FGF-7) expression and when used in a growth factor cocktail, applied to 
the cornea after infection, increased β-defensins 2 (mRNA and protein) and 3 
(mRNA). These data compliment prior work from this laboratory in which we 
showed that in the cornea, both defensins are protective in a murine (BALB/c, 
resistant) model of P. aeruginosa-induced microbial keratitis (Wu et al., 2009a; 
Wu et al., 2009b); this inbred strain also was shown to have increased levels of 
VIP when compared with B6 mice after infection (Szliter et al., 2007). 
VIP also increased HGF expression at both mRNA and protein levels 
(ELISA and immunostaining). This growth factor has anti-inflammatory properties 
(Gong et al., 2006), in that it can target vascular endothelial cells and disrupt NF-
κB signaling (Giannopoulou et al., 2008), critical to regulating inflammation. We 
also have reported that VIP treatment of susceptible B6 mice, decreased pro-
inflammatory cytokines, including but not limited to IFN-γ, IL-1β, TNF-α, and MIP-
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2 and enhanced protective cytokines such as TGF-β and IL-10 (Szliter et al., 
2007). TGF-β, in addition to its regulation of immune responses, is also 
profibrotic (Li et al., 2006), which may reflect increased wound healing in the VIP- 
and/or growth factor-treated mice in which stromal destruction is diminished. 
Because the present study has shown that HGF levels are enhanced after VIP 
treatment in B6 mice, it is not inappropriate to suggest that the observed 
protective effects of VIP could be affected by HGF enhancement. 
Immunostaining for VEGF-A was observed in both epithelium and stroma at 5 
days p.i., confirming the ELISA data and providing information regarding protein 
localization. High expression of VEGF-A mRNA in the newly formed epidermis 
after wounding (Hong et al., 2004) is somewhat consistent with our data, which 
shows a more modest effect. Elevated expression of VEGF-A may be indicative 
of its exerting its growth factor functions to induce healing, cell division, migration, 
cell survival, and proliferation (Rini and Small, 2005). In addition to its growth 
factor properties, VEGF-A can also regulate angiogenesis (Nicosia, 1998; Tille et 
al., 2001). Data from the present study show that VIP upregulates VEGFR2 
protein levels more than two-fold at 5 days p.i. These data indicate that VIP, via 
up-regulation of VEGFR2 has an angiogenic effect that is beneficial to the 
avascular cornea for disease resolution, (confirmed by photography using a slit 
lamp). The data are also consistent with the tenet that the cornea must balance 
its usually high threshold for resisting vascular ingrowth (corneal 
hemangiogenesis) with an ability to react to sight-threatening injuries (e.g., P. 
aeruginosa), with a robust and rapid angiogenic response, required to enhance 
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immune defenses (Cursiefen et al., 2006; Streilein, 2003). We hypothesize that 
inflammation is reduced through the actions of VIP on pro-inflammatory cytokines 
and chemokines, but also, with increased VEGF-A and R2 protein levels, as 
reported herein, immune cells are better able to enter the cornea, more rapidly 
participate in bacterial disposal, thus limiting bacterial-induced stromal damage; 
this is followed by healing through the role of VIP in promoting anti-inflammatory 
cytokines (Szliter et al., 2007), and modulating growth factor production as 
shown herein. These data also are consistent with other studies using a rat 
sponge model for quantitative assessment of angiogenesis which have shown 
that VIP treatment improved angiogenesis in sponge sections (Hu et al., 1996). 
In vitro studies have shown that exogenous application of EGF can 
stimulate corneal epithelial cell migration (Nishida et al., 1992) which may have a 
positive effect in microbial keratitis, contributing to restoration of epithelial barrier 
function. 
In addition, other studies have shown that topical application of EGF and 
FGF can promote wound healing in several types of corneal wound models, 
(Baldwin and Marshall, 2002; Forster et al., 2008; Fredj-Reygrobellet et al., 1987; 
Nishida et al., 1992) consistent with the lack of perforation in VIP-treated mice in 
which these growth factors are elevated. In this regard, topical treatment with a 
growth factor cocktail containing EGF, FGF, and HGF provided evidence that at 
least some of the effects seen with VIP may be evoked through these growth 
factors. For example, in growth factor-treated eyes, only one of five versus all 5 
corneas of PBS-treated eyes perforated; MIP-2, a chemokine that attracts 
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neutrophils (PMN) into the cornea2 mRNA was reduced; while TGF-β, an anti-
inflammatory cytokine, was up-regulated as shown before with VIP treatment 
(Szliter et al., 2007). Growth factor treatment also significantly increased β-
defensins 2 and 3 mRNA expression at 5 days p.i. and β-defensin 2 staining was 
enhanced at 5 days p.i. in both epithelium and stroma. These data are consistent 
with a previous study showing that KGF increased β-defensin 2 expression levels 
in a skin model expressing KGF/FGF-7 (Erdag et al., 2004). Most importantly, 
after growth factor treatment, bacterial counts also were reduced at 1, 3, and 5 
days p.i., but were significant only at 1 day p.i. These data suggest that there is a 
delay in bacterial growth in the growth factor-treated cornea which may reflect 
less stromal damage which could be permissive to bacterial growth. 
Overall, this study provides evidence that VIP modulates growth factors, 
angiogenic molecules (in both epithelium and stroma), β-defensin production, 
and bacterial counts and that many of the effects observed with VIP treatment 
can be compensated for through exogenous growth factor delivery.  
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Figure 5. mRNA and protein expression patterns after VIP. EGF (A) 
mRNA levels were significantly increased in VIP- versus PBS-treated B6 mice in 
the normal, uninfected cornea and at 3 days p.i. mRNA levels of FGF (C) were 
unchanged between the two groups. HGF mRNA expression levels (E) were 
significantly increased by VIP in normal, uninfected cornea and at and 1 and 3 
days p.i. EGFR mRNA levels (G) were increased after VIP treatment at 5 and 7 
days p.i. (n = 5 per group per time per treatment for two experiments = 80 mice). 
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ELISA analysis: When compared with PBS, VIP significantly increased EGF 
protein expression (B) at 5 and 7 days p.i., but earlier in the normal cornea and at 
1 day p.i., EGF protein levels were lower after VIP treatment. For FGF (D), VIP 
increased protein levels only at 7 days p.i. For HGF (F), VIP significantly 
increased protein levels at 1 and 5 days p.i. No significant changes were seen at 
other times tested for all assays (n = 5 per group per time per treatment for two 
experiments = 60 mice). Results for mRNA and protein data are mean ± SD.  
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Figure 6. VEGF mRNA, protein, and photography with a slit lamp to 
document VIP regulation. VIP versus PBS modestly elevated mRNA expression 
of VEGF-A (A) only in the normal, uninfected cornea. VEGFR1 (C) mRNA levels 
were increased by VIP in the normal, uninfected cornea, but levels decreased at 
5 days p.i. VIP treatment increased VEGFR2 (E) in the normal cornea No 
significant changes were seen at other times tested for all assays (n = 5 per 
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group per time per treatment for two experiments = 40 mice). ELISA analysis: For 
VEGF-A (B), VIP versus PBS increased protein levels at 7 days p.i. For VEGFR1 
(D), levels were unchanged at all times tested. For VEGFR2 (F), protein levels 
were increased only at 7 days p.i. Photography using a slit lamp showed that VIP 
treatment decreased opacity and increased peripheral corneal vascularization 
when compared with PBS (D) treatment (magnification, ×15; n = 5 per group per 
time per treatment for two experiments = 40 mice). Results for mRNA and protein 
data are mean ± SD. (G, H) Photographs reprinted with permission from Szliter 
EA, Lighvani S, Barrett RP, Hazlett LD. Vasoactive intestinal peptide balances 
pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected 
cornea and protects against corneal perforation. J Immunol. 2007;178:1105–1114. 
Copyright 2007. The American Association of Immunologists, Inc.  
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Figure 7. Immunostaining at 1 day p.i. for growth factors and VEGF-A. 
EGF immunostaining was slightly increased in PBS- (A) versus VIP- (B) treated 
mice (stromal as shown in the insets and epithelial). For FGF, epithelial staining 
was seen and similar between groups (C, D). For HGF VIP enhanced stromal 
immunostaining, while more epithelial staining was seen in the PBS group (E, F). 
For VEGF-A, staining was similar between groups in both the epithelium and 
stroma (G, H, and insets). An example of a negative control (primary antibody 
substituted with species-specific IgG) shows lack of positive immunostaining (I, J) 
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seen with each of the factors tested. Green: Sytox green nuclear label; red: Alexa 
Fluor 594 secondary antibody staining; n = 5 per group per treatment for two 
experiments = 20 mice).  
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Figure 8. Immunostaining at 5 days p.i. for growth factor and VEGF-A. At 
this time, EGF, FGF, HGF, and VEGF-A epithelial and stromal staining was more 
intense in VIP- (B, D, F, H) versus PBS- (A, C, E, G) treated corneas. An 
example of a negative control (primary antibody substituted with species-specific 
IgG) shows lack of positive immunostaining (I, J) seen with each of the factors 
tested. Green: Sytox green nuclear label; red: Alexa Fluor 594 secondary 
antibody staining. Magnification, ×100; n = 5 per group per treatment for two 
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experiments = 20 mice.  
 
 - 47 -
 
Figure 9. Topical growth factor treatment and assessing disease response 
by clinical evaluation and RT-PCR. Clinical scores (A) indicated statistically 
significant differences at 5 (P < 0.05) days p.i. between groups. Photographs 
taken with a slit lamp at 5 days p.i. showed a worsened disease response 
(perforation) when comparing control (B) versus growth factor (C) treatment. 
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Magnification, ×6 (n = 5 per group per treatment for two experiments = 20 mice). 
mRNA levels (D–I) showed a significant decrease in MIP-2 (D), no change in 
TNF-α (E), and increased TGF-β (F), VEGF-A (G), and β-defensins 2 (H) and 3 (I) 
in growth factor versus control treated eyes (n = 5 per group per treatment for 
two experiments = 20 mice). Results are shown as mean ± SD.  
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Figure 10. Immunostaining and bacterial counts after topical growth factor 
treatment. At 5 days p.i., β-defensin 2 epithelial and stromal staining was more 
intense in growth factor- (B and inset) versus PBS- (A) treated corneas. At this 
time, negligible staining for β-defensin 3 was seen after either growth factor (D) 
 
 - 50 -
or PBS (C) treatment. Controls, in which the primary Ab was replaced by IgG, 
were negative for immunostaining (E, F) for both defensins. Green: Sytox green 
nuclear label; red: Alexa Fluor 594 secondary antibody staining (n = 5 per group 
per treatment for two experiments = 20 mice). (G) Bacterial counts: Growth factor 
(grey filled bar) versus PBS (unfilled bar) treatment reduced bacterial plate 
counts at 1, 3, and 5 days p.i., but were significant only at 1 day p.i. (n = 5 per 
group per treatment for two experiments = 60 mice). Results are shown as mean 
± SD.  
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Chapter 3 
VASOACTIVE INTESTINAL PEPTIDE DOWNREGULATES 
PROINFLAMMATORY TLRS WHILE UPREGULATING ANTI-INFLAMMATORY 
TLRS IN THE INFECTED CORNEA 
3.1 Abstract 
TLRs recognize microbial pathogens and trigger an immune response, but 
their regulation by neuropeptides, such as VIP, during P. aeruginosa corneal 
infection remains unexplored. Therefore, B6 mice were injected i.p. with VIP, and 
mRNA, protein, and immunostaining assays were performed. After VIP treatment, 
PCR array and real-time RT-PCR demonstrated that pro-inflammatory TLRs 
(Chuk, IRAK1, TLR1, TLR4, TLR6, TLR8, TLR9, and TRAF6) were down-
regulated, whereas anti-inflammatory TLRs (SIGIRR and ST2) were up-regulated. 
ELISA showed that VIP modestly down-regulated phosphorylated IKKα but up-
regulated ST2 ~2-fold. SIGIRR was also up-regulated, whereas TLR4 
immunostaining was reduced in cornea; all confirmed the mRNA data. To 
determine whether VIP effects were cAMP dependent, mice were injected with 
small interfering RNA for type 7 adenylate cyclase (AC7), with or without VIP 
treatment. After silencing AC7, changes in mRNA levels of TLR1, TRAF6, and 
ST2 were seen and unchanged with addition of VIP, indicating that their 
regulation was cAMP dependent. In contrast, changes were seen in mRNA levels 
of Chuk, IRAK1, 2, TLR4, 9 and SIGIRR following AC7 silencing alone; these 
were modified by VIP addition, indicating their cAMP independence. In vitro 
studies assessed the effects of VIP on TLR regulation in macrophages and 
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Langerhans cells. VIP down-regulated mRNA expression of pro-inflammatory 
TLRs while up-regulating anti-inflammatory TLRs in both cell types. Collectively, 
the data provide evidence that VIP down-regulates pro-inflammatory TLRs and 
up-regulates anti-inflammatory TLRs and that this regulation is both cAMP 
dependent and independent and involves immune cell types found in the infected 
cornea. 
3.2 Introduction 
Keratitis induced by P. aeruginosa progresses rapidly and is characterized 
by a suppurative stromal infiltrate with a marked mucopurulent exudate. Other 
untoward characteristics include inflammatory epithelial edema, ocular pain and 
redness, stromal ulceration, and often, decreased vision (Hazlett, 2004). 
Experimentally, infection with P. aeruginosa leads to corneal perforation in strains 
of mice, such as C57BL/6 (B6; susceptible), whereas less severe disease is seen 
in similarly challenged BALB/c (resistant) animals (Hazlett et al., 2000). In 
contrast, treatment of B6 mice with VIP promotes better disease outcome 
postinfection with P. aeruginosa, mainly through regulation of cytokine production 
and subsequent alteration of the host inflammatory cell response (Szliter et al., 
2007). Recent studies from this laboratory provided further information regarding 
the anti-inflammatory effects of VIP and showed that it modulates keratitis 
through regulation of growth factors, angiogenic molecules, and β defensins in 
the infected cornea, contributing to healing (Jiang et al., 2011). However, the role 
of VIP in the regulation of TLRs has not been well-defined, despite the fact that 
other studies demonstrated that TLRs play an important role in ocular immune 
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defense (Yu and Hazlett, 2006). They direct the ocular immune response by 
differentially regulating a variety of events, including bacterial killing, 
polymorphonuclear leukocyte infiltration, and cytokine expression at both mRNA 
and protein levels (Huang et al., 2005; Huang et al., 2007; Huang et al., 2006a; 
Huang et al., 2006b). In particular, TLR4, a specific receptor for LPS contained in 
the outer membrane of various Gram-negative bacteria, is required for host 
resistance against P. aeruginosa in the infected cornea (Huang et al., 2006a). In 
fact, upon activation by P. aeruginosa, both TLR4 and TLR5 on corneal 
macrophages were shown to regulate P. aeruginosa keratitis through MyD88-
dependent and -independent pathways (Sun et al., 2010). Therefore, it is 
important to understand which TLRs are regulated by VIP, as well as the 
mechanisms involved during microbial keratitis. In this regard, studies suggested 
that VIP can signal through cAMP-dependent or -independent pathways (Chorny 
et al., 2006), but it is not known whether this is important in VIP regulation of 
TLRs in other diseases (Gomariz et al., 2007) or bacterial keratitis. 
Thus, the current studies investigated the expression of TLR-signaling 
pathways in P. aeruginosa-infected corneas, with or without VIP treatment, to 
determine whether it regulates their expression to favor disease resolution. Our 
data provide evidence that VIP treatment down-regulates pro-inflammatory TLRs 
while up-regulating anti-inflammatory TLRs at both the mRNA and protein levels 
in the cornea after P. aeruginosa infection and that, mechanistically, two 
transduction pathways, cAMP dependent and independent, are involved. 
Furthermore, in vitro studies suggest that at least two cell types in the cornea 
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may be responsive, because VIP reduced pro-inflammatory TLRs and increased 
anti-inflammatory TLRs in both LPS-stimulated elicited peritoneal macrophages 
and XS52 (Langerhans) cells. 
3.3 Materials and Methods 
Infection 
Eight-week-old female B6 mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Mice were anesthetized with ethyl ether and placed 
beneath a stereoscopic microscope at ×40 magnification. The cornea of the left 
eye was wounded (Rudner et al., 2000), and a 5 μl-aliquot containing 1.0 × 106 
CFU P. aeruginosa (strain 19660; American Type Culture Collection, Manassas, 
VA) was topically delivered. Animals were treated humanely and in compliance 
with the Association for Research in Vision and Ophthalmology Statement on the 
Use of Animals in Ophthalmic and Vision Research. 
VIP treatment 
Treatment with synthetic VIP was described previously (Szliter et al., 2007) 
at a dosage reported to be efficacious in a lethal endotoxemia model (Delgado et 
al., 1999b). In brief, using that dosage, B6 mice received daily i.p. injections of 
VIP (5 nM in 100 μl sterile PBS) at 1 d before infection (day −1) through a 
maximum of 7 d postinfection (p.i.). Control mice were injected similarly with 
sterile PBS (100 μl). 
RNA interference 
Use of small interfering RNA (siRNA) was described in previous work from 
this laboratory (Wu et al., 2009a). For the current studies, siRNA for type 7 
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adenylate cyclase (AC7) or an appropriate scrambled control (Santa Cruz 
Biotechnology, Santa Cruz, CA) was injected subconjunctivally (5 μl/mouse at a 
concentration of 8 μM) into the left eye of B6 mice (n = 5/group/time) 1 d before 
infection, with or without VIP treatment (described above). AC7 (4 μM) was 
applied topically to the infected corneas (5 μl/mouse/time) once on the day of 
infection and twice on days 1 and 3 p.i. Corneas from scrambled control, silenced 
AC7, or silenced AC7 plus VIP-treated (n = 5/group/time) mice were individually 
collected at 5 d p.i. and processed for RT-PCR (described below). Using a similar 
assay, the efficacy of silencing AC7 in cornea (n = 5/group/time) was confirmed 
by real-time RT-PCR (5 d p.i.). 
Real-time RT-PCR 
Total RNA was isolated from individual corneas (n = 5/group/time) or cells 
using RNA-Stat 60 (Invitrogen, Carlsbad, CA), per the manufacturer’s 
recommendations, and quantitated spectrophotometrically (260 nm). One 
microgram of total RNA was reverse transcribed using MMLV reverse 
transcriptase. The 20-μl reaction mixture contained 200 U MMLV-reverse 
transcriptase, 10 U RNasin, 500 ng oligodeoxythymidine primers, 10 mM 
deoxyribonucleotide triphosphate, 100 mM DTT, and MMLV reaction buffer 
(Invitrogen). cDNA was amplified using SYBR Green Master Mix (SABiosciences, 
Frederick, MD), per the manufacturer’s recommendation. Briefly, the reaction 
system contained 10 μl SYBR Green PCR Master Mix, 0.5 μM primers, and 2 μl 
cDNA (diluted 1/10) in diethyl pyrocarbonate water. All primer sets for the PCR 
array were purchased as a 96-well plate (RT2 Profiler TLR Signaling Pathway 
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PCR Array; SABiosciences). The individual primer sets were designed using 
PrimerQuest (Integrated DNA Technologies, Cambridge, MA). Sequences of 
primers for β-actin, AC7, conserved helix-loop-helix ubiquitous kinase inhibitor of 
NF-κB kinase subunit α (Chuk), IRAK1, IRAK2, TLR1, TLR4, TLR6, TLR8, TLR9, 
TNFR-associated factor (TRAF)6, SIGIRR, and ST2 are shown (Table 2). 
ELISA 
Protein levels of TLR-associated molecules were tested by ELISA. 
Corneas from PBS- and VIP-treated B6 mice were individually collected (n = 
5/group/time) from normal uninfected and infected mice at 1 and 7 d p.i. For total 
Chuk (IKKα) and p-IKKα (Cell Signaling Technology, Danvers, MA), corneas were 
homogenized in 0.5 ml lysis buffer (Cell Signaling Technology) with 1 mM PMSF 
(Sigma, St. Louis, MO) and protease inhibitor (1 tablet/10 ml; Roche, Indianapolis, 
IN). For ST2 (R&D Systems, Minneapolis, MN), corneas were homogenized in 
0.5 ml PBS with 0.1% Tween 20 and protease inhibitor (as above). All samples 
were centrifuged at 13,000 rpm for 5 min, and an aliquot of each supernatant 
was assayed in duplicate for total IKKα, p-IKKα, and ST2, per the manufacturer’s 
instructions. 
Western blot 
Corneas (n = 5/group/time) were collected from PBS- and VIP-treated 
normal uninfected and infected B6 mice at 1 and 5 d p.i. Pooled corneas (n = 
5/group) were lysed in 250 μl radio immunoprecipitation assay lysis buffer (Santa 
Cruz Biotechnology) and homogenized for 15 min. Tissue debris was pelleted by 
centrifugation for 10 min at 12,000 rpm, and protein concentration of the 
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supernatant was determined by bicinchoninic acid (Bio-Rad) protein assay. 
Supernatants were separated on 10% SDS-PAGE, after loading an 80-μg sample 
in each lane; as a control, recombinant murine SIGIRR (15 ng; R&D Systems) 
was similarly loaded. The electrophoretically separated material was transferred 
to a supported nitrocellulose membrane (Bio-Rad) and blocked in a 5% solution 
of nonfat dry milk prepared in 1× PBS and 0.05% Tween 20. Blots were 
incubated with primary goat anti-mouse SIGIRR Ab (R&D Systems) diluted in 
PBS overnight (4°C), washed three times for 10 min each with TBST, detected 
with HRP-conjugated secondary Ab (R&D Systems) diluted 1/1000 in PBS 
containing 5% nonfat milk, and developed using the ECL method (PerkinElmer, 
Waltham, MA), per the manufacturer’s protocol. The blot was scanned on a 
FluorChem E imaging system (Cell Biosciences, Santa Clara, CA), and band 
relative integrated density value was analyzed by AlphaView software (Cell 
Biosciences). 
Immunofluorescent staining 
Normal, uninfected and infected eyes were enucleated from VIP- or PBS-
treated B6 mice (n = 5/group/time) at 1 and 5 d p.i. Tissue was immersed in 1× 
Dulbecco’s PBS (Mediatech, Herndon, VA), embedded in Tissue-Tek OCT 
compound (Miles, Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer-thick 
sections were cut, mounted on polylysine-coated glass slides, and incubated in a 
moist chamber at 37°C overnight. After a 2-min acetone fixation, nonspecific 
staining was blocked with 10 mM sodium phosphate buffer containing 2.5% BSA 
and donkey IgG (1:100) for 30 min at room temperature. For immunostaining, 
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sections were incubated for 1 h each with goat anti-mouse TLR4 (Santa Cruz 
Biotechnology), followed by an Alexa Fluor 594-conjugated donkey anti-goat 
secondary Ab (1:1500, Invitrogen). Sections were incubated for 2 min with 
SYTOX Green nuclear acid stain (1:20,000; Lonza, Walkersville, MD). Controls 
were treated similarly, but the primary Ab was replaced with the same host IgG. 
Finally, sections were visualized (TLR4+ staining = red), and digital images were 
captured with a Leica TCS SP2 confocal laser-scanning microscope (Leica 
Microsystems, Bannockburn, IL). 
Cell isolation, culture, and treatment 
Peritoneal macrophages were elicited and isolated from B6 mice, as 
described before (Szliter et al., 2007). Briefly, cells were induced into the 
peritoneal cavity by i.p. injection of 1.0 ml 3% Brewer’s thioglycollate medium 
(Becton Dickinson, Sparks, MD) 5 d before harvest (n = 12 mice). Cells were 
collected by peritoneal lavage with DMEM and stained with trypan blue (1:1); 
viable cells (>95%) were counted using a hemacytometer. After a differential cell 
count, cells were collected and pooled, and 3 × 106 macrophages/well (five 
wells/treatment) were seeded into six-well plates. Nonadherent cells were 
removed 24 h later, and isolated macrophages were used for the in vitro-
stimulation assays described below. Mouse XS52 (Langerhans) cells were 
cultured in complete RPMI 1640 with 10% FCS (both from Life Technologies, 
Grand Island, NY) supplemented with 0.5 ng/ml murine rGM-CSF (Life 
Technologies), as described previously (Huang et al., 2005). These cells (capable 
of presenting protein Ag to primed CD4+ T cells) were derived from newborn 
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BALB/c mouse epidermis as stable long-term cell lines (dendritic shaped, 
CD45+/E-cadherin+ and B7-1-) (Xu et al., 1995). After differential cell count, 3 × 
106 XS52 (Langerhans) cells/well (five wells/treatment) were seeded into six-well 
plates. Both cell types were treated with 1 μg ultrapure LPS (Escherichia coli 
01111:B4 strain; which only activates the TLR4 pathway; InvivoGen, San Diego, 
CA), with or without VIP (10−9 M). For both macrophage and XS52 (Langerhans) 
cell experiments, which were repeated similarly once (n = 2 experiments for each 
cell type), cells from each well were collected, mRNA was extracted and assayed 
in duplicate by real-time RT-PCR (described above), and the data were analyzed 
statistically. 
Langerhans cell staining and quantitation 
Normal, uninfected corneas were harvested at 1 and 3 d p.i. and placed in 
0.02 mol/l EDTA (pH 7.2) for 1 h at 37°C for epithelial removal and Langerhans 
cell staining. Epithelial sheets were fixed in cacodylate-buffered formaldehyde for 
20 min at 4°C, washed four times with cold 0.1 mol/l cacodylate buffer, and 
incubated in ADPase substrate solution containing ADPase buffer, 2% lead 
nitrate, and ADP (5 mg/ml; Sigma) for 15 min at 37°C. Sheets were washed four 
times with trismaleate buffer (pH 7.2), developed for 5 min in a 1:10 ammonium 
sulfide solution, washed three times with buffer, mounted onto slides with glycerol, 
flattened, and coverslipped (Hazlett et al., 2002). Epithelial sheets were observed 
and photographed with a Zeiss Axiophot microscope with Axiocam digital 
imagery (Carl Zeiss; Morgan Instruments, Cincinnati, OH) at ×375, and the 
number of cells was quantitated/field (n = 12; field size = 270 μm2) by two 
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investigators who were blinded to the treatment. Staining of Langerhans cells for 
ADPase activity was done previously and was shown to provide data similar to 
immunostaining these cells with surface markers, such as DEC205 (Hazlett et al., 
2002). 
Statistics 
Two-way ANOVA, followed by the Bonferroni posttest, was used for 
analysis of the data shown in Figs. 11, 12, and 17 (Prism 3.0; GraphPad 
Software, La Jolla, CA). One-way ANOVA, followed by the Tukey posttest, was 
used for the data shown in Figs. 14–16 (SPSS, Chicago, IL). For each test, 
differences were considered significant at p < 0.05, and data shown are mean ± 
SEM. Each experiment was performed at least twice, and combined data are 
shown, with the exception of Figs. 15 and 16, in which representative data from a 
single similar experiment are provided. Infection of mice, confocal microscopy, 
and Langerhans cell quantitative studies were done in a blinded fashion. 
3.4 Results 
PCR array and real-time RT-PCR 
To determine the effects of VIP treatment on the regulation of TLRs in 
cornea during bacterial keratitis, mRNA levels were tested by RT-PCR (Table 2) 
and 84 TLR-related genes were profiled by PCR array at 3 d p.i. VIP treatment 
decreased the expression (>3-fold) of 21 genes compared with PBS-treated 
controls (Table 3). RT-PCR was used to confirm the array data and to test TLR4 
(Huang et al., 2006a) and IRAK1 (Deng et al., 2006; Hacker et al., 2011), which 
are important in Pseudomonas-induced infections, but were not changed on the 
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PCR array greater >3-fold (TLR4, −1.11 and IRAK1, −2.9). Negative regulators of 
TLRs (ST2 and SIGIRR), not included on the PCR array, that were shown 
previously to promote resistance to P. aeruginosa keratitis  (Huang et al., 2007; 
Huang et al., 2006b) were also tested. 
VIP significantly down-regulated mRNA expression for TLR1 only at 7 d p.i. 
(Fig. 11A, p < 0.01). However, compared with PBS treatment, VIP decreased 
mRNA levels of TLR4 only at 1 d postinfection (Fig. 11B, p < 0.001). VIP also 
down-regulated mRNA levels of TLR6 at 5 and 7 d p.i. (Fig. 11C, p < 0.05 and p 
< 0.001, respectively), for TLR8 only at 7 d p.i. (Fig. 11D, p < 0.001), and for 
TLR9 only at 5 d p.i. (Fig. 11E, p < 0.001). Compared with PBS treatment, VIP 
treatment also decreased mRNA expression of TLR adaptor molecule IRAK1 at 1 
and 5 d p.i. (Fig. 11F, p < 0.001 and p < 0.001, respectively), but no differences 
were seen between the groups for IRAK2 (Fig. 11G). TRAF6, which interacts with 
IRAK1 (Cao et al., 1996), also was reduced at the mRNA level by VIP treatment 
compared with PBS treatment at 5 and 7 d p.i. (Fig. 11H, p < 0.05 and p < 0.001, 
respectively). mRNA levels of Chuk, a downstream molecule of the IRAK–
TRAF6-signaling pathway, which regulates NF-κB expression (Cao et al., 1996), 
also was down-regulated by VIP at 1 and 7 d p.i. (Fig. 11I, p < 0.01 and p < 0.001, 
respectively). In contrast, VIP treatment increased SIGIRR mRNA levels at 5 and 
7 d p.i. (Fig. 11J, p < 0.001 for both). However, levels in both groups decreased 
at 1 d p.i. ST2 mRNA levels also were increased by VIP treatment at all times 
tested, but it was significant only at 7 d p.i. (Fig. 11K, p < 0.05). 
ELISA and Western blot 
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ELISA and/or Western blot was used to selectively confirm the mRNA data 
for total IKKα (Chuk), p-IKKα, ST2, and SIGIRR. For total IKKα (Fig. 12A), there 
was no significant difference between PBS and VIP treatment at any time tested. 
However, compared with PBS treatment, VIP treatment slightly down-regulated 
p-IKKα protein expression only at 7 d p.i. (Fig. 12B, p < 0.05). In contrast, protein 
levels of ST2 (Fig. 12C) were significantly enhanced by VIP treatment compared 
with PBS treatment at 7 d p.i. (p < 0.001), not different at 1 d p.i., and not 
detectable in either normal sample. SIGIRR protein (Fig. 12D, 12E) was 
constitutively expressed at similar levels in normal PBS- and VIP-treated mouse 
cornea. At 1 d p.i., greater levels of SIGIRR (p < 0.001) were observed after VIP 
treatment, with no difference between the two groups at 5 d p.i. 
TLR4 immunostaining 
Immunohistochemistry was used to spatially localize TLR4 (red staining) in 
the cornea of VIP- versus PBS-treated B6 mice at 1 and 5 d p.i. At 1 d p.i., 
reduced TLR4 staining was seen after VIP treatment (Fig. 13B), compared with 
PBS treatment (Fig. 13A), in corneal epithelium and stroma. At 5 d p.i., compared 
with PBS treatment, VIP treatment further reduced TLR4 epithelial and stromal 
staining (compare Fig. 13D with 13C). Controls in which primary Ab was 
substituted with species-specific IgG were negative after PBS (Fig. 13E) or VIP 
(Fig. 13F) treatment at 1 or 5 d p.i. (data not shown). 
Silencing AC7 
To determine whether the anti-inflammatory effect of VIP on TLRs was 
cAMP dependent, siRNA was used in vivo to knock down AC7; it was selected 
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because, among the 10 mammalian adenyl cyclase isotypes, AC7 is highly 
expressed in the immune system (Duan et al., 2010). When tested at 5 d p.i., RT-
PCR confirmed that silencing AC7 versus scrambled control treatment 
significantly decreased AC7 mRNA levels (Fig. 14A, p < 0.01) and that silencing 
plus VIP treatment did not reverse the effect. Furthermore, at this time, silencing 
AC7 increased mRNA levels of TLR1 (Fig. 14B), whereas TRAF6 (Fig. 14C) and 
ST2 (Fig. 14D) were decreased (p < 0.05, p = 0.001, and p < 0.01, respectively). 
Silencing plus VIP injection did not change the effect, indicating that VIP 
regulation of these TLRs is cAMP dependent. mRNA levels of pro-inflammatory 
TLRs, including Chuk (Fig. 14E), IRAK1 (Fig. 14F), TLR4 (Fig. 14G), TLR9 (Fig. 
14H), and IRAK2 (Fig. 14I), were increased after silencing compared with 
scrambled control treatment (p < 0.01, p < 0.01, p = 0.001, p = 0.01, and p < 0.05, 
respectively); levels of the anti-inflammatory TLR SIGIRR were decreased (Fig. 
14J, p = 0.001). Silencing plus VIP injection changed the effect (Chuk: p < 0.001; 
IRAK1: p < 0.05; TLR4: p = 0.001; TLR9: p < 0.01; IRAK2: p < 0.05; SIGIRR: p < 
0.05), indicating that VIP regulation of these molecules is cAMP independent. No 
significant changes in mRNA levels of TLR6 (Fig. 14K) were seen with AC7 
siRNA treatment, but VIP plus silencing decreased mRNA levels of TLR6 (p < 
0.05), suggesting the possibility of its regulation by another adenyl cyclase 
isoform (Song et al., 2007). No effects were seen for TLR8 (Fig. 14L), suggesting 
that it is independent of AC7 and VIP regulation. 
In vitro studies: macrophages 
To provide some indication of which cells may be involved in VIP 
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regulation of TLRs, peritoneal exudate macrophages and XS52 (Langerhans) 
cells were tested in an in vitro assay. Compared with media control, ultrapure 
LPS (only activates the TLR4 pathway) significantly increased TLR1 (Fig. 15A, p 
< 0.001), TLR4 (Fig. 15B, p < 0.01), MyD88 (Fig. 15C, p < 0.001), IRAK1 (Fig. 
15D, p < 0.01), and TRAF6 (Fig. 15E, p < 0.001) mRNA, with no effect on ST2 
mRNA (Fig. 15G). However, SIGIRR mRNA (Fig. 15F, p < 0.001) was decreased 
after LPS stimulation compared with media control stimulation. Compared with 
LPS alone, LPS plus VIP significantly decreased mRNA levels of TLR1 (Fig. 15A, 
p < 0.05), TLR4 (Fig. 15B, p < 0.01), MyD88 (Fig.15C, p < 0.001), IRAK1 (Fig. 
15D, p < 0.001), and TRAF6 (Fig. 15E, p < 0.001) but increased ST2 (Fig. 15G, p 
< 0.05); no difference was seen for SIGIRR (Fig. 15F). Cultured cells treated with 
VIP alone showed no significant difference compared with media-treated controls 
for any of the molecules tested. 
In vitro studies: XS52 (Langerhans) cells 
LPS versus media control treatment of XS52 (Langerhans) cells 
significantly increased mRNA levels of TLR1 (Fig. 16A, p < 0.001), TLR4 (Fig. 
16B, p < 0.001), MyD88 (Fig. 16C, p < 0.001), and TRAF6 (Fig. 16E, p < 0.001) 
but decreased ST2 (Fig. 16G, p < 0.001). IRAK1 (Fig. 16D) and SIGIRR (Fig. 16F) 
mRNA levels were unchanged after LPS stimulation compared with media control 
stimulation. Compared with LPS alone, LPS plus VIP significantly decreased 
mRNA levels of MyD88 (Fig. 16C, p < 0.05) and TRAF6 (Fig. 16E, p < 0.001) but 
increased SIGIRR mRNA expression (Fig. 16F, p < 0.001). Compared with LPS 
alone, LPS plus VIP did not significantly change mRNA levels of TLR1 (Fig. 16A), 
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TLR4 (Fig. 16B), IRAK1 (Fig. 16D), or ST2 (Fig. 16G). Cultured cells treated with 
VIP alone did not differ from media-treated controls for any of the molecules 
tested. 
Langerhans cell detection and quantitation 
In normal, uninfected eyes, dendritic-shaped Langerhans cells were 
detected in the peripheral cornea/conjunctiva of PBS-treated (Fig. 17A) and VIP-
treated (Fig. 17B) mice; quantitatively, they were slightly decreased (not 
significantly) after VIP treatment (Fig. 17G). At 1 d p.i., rounded, motile 
Langerhans cells appeared to be decreased in the conjunctiva and peripheral 
cornea of VIP-treated mice (Fig. 17D) compared with PBS-treated mice (Fig. 
17C), and quantitation showed that the difference was significant (p < 0.05, Fig. 
17G). By 3 d p.i., the cell number appeared similar in PBS-treated (Fig. 17E) and 
VIP-treated (Fig. 17F) mice; when quantitated, no difference was seen between 
the two groups (Fig. 17G). 
3.5 Discussion 
 VIP regulates a wide variety of immune reactions; among its numerous 
anti-inflammatory functions, it participates in the maintenance of immune 
homeostasis (Gomariz et al., 2010; Smalley et al., 2009). Previously, our 
laboratory showed that, in the cornea of B6 mice infected with P. aeruginosa, VIP 
treatment regulates cytokine production through up-regulation of VIP receptor 1 
on inflammatory cells, leading to less stromal destruction and prevention of 
corneal perforation (Szliter et al., 2007). Recent work provided further evidence 
that similar VIP treatment of B6 mice also has an indirect effect: it modulates 
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growth factors, angiogenic molecules, and defensins in the infected cornea, 
which, in turn, promote healing (Jiang et al., 2011). In addition, other studies 
showed that VIP down-regulates pro-inflammatory TLRs and related molecules in 
several nonocular disease models (Gomariz et al., 2007). TLRs, important in 
innate immunity, are critical for recognition of conserved pathogen-associated 
molecular patterns, through TLR/IL-1R expressed on the surface of various cell 
types, to trigger cytokine/chemokine production (Chtarbanova and Imler, 2011; 
Medzhitov and Janeway, 2000). In this regard, previous studies from this 
laboratory and other investigators showed that TLR1 (Yuan and Wilhelmus, 
2010), TLR3 (Johnson et al., 2008), TLR4 (Huang et al., 2006a), and TLR9 
(Huang et al., 2005) play important roles in the pathogenesis of experimentally 
induced keratitis. However, VIP regulation of TLRs during these diseases has not 
been characterized. Thus, the current study, using a PCR array to profile 84 TLR-
related genes, provided an overview of the ability of VIP to provide master 
regulation of TLRs and signaling-pathway molecules in bacterial keratitis. 
Twenty-one genes were down-regulated ≥ 3-fold by VIP, and several of them 
were selected for further confirmation by RT-PCR. The results indicated that VIP 
reduced pro-inflammatory TLRs and related molecules (TLR1, TLR4, TLR6, 
TLR8, TLR9, IRAK1, TRAF6, and Chuk), which agreed well with the array data. 
The array did not contain two anti-inflammatory TLRs important in promoting the 
resistance response of BALB/c mice to P. aeruginosa: SIGIRR (Huang et al., 
2006b) and ST2 (Huang et al., 2007); however, when tested by RT-PCR, these 
genes, in general, were up-regulated by VIP treatment. Immunohistochemistry 
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data further confirmed that VIP decreased TLR4 protein expression in both 
epithelial and stromal layers of the cornea. These results also are consistent with 
previous studies showing that VIP inhibits or even reverses TLR2 (Foster et al., 
2007), TLR3 (Lee et al., 2009), and TLR4 (Arranz et al., 2008a; Arranz et al., 
2008b) expression or their stimulated signaling pathways in other nonocular 
disease models. 
On ligand binding, TLRs recruit adaptor molecules, such as IRAK and 
TRAF6, to their intracellular signaling domain, leading to the activation of several 
kinases, as well as the transcription factor, NF-κB, thereby directly up-regulating 
immune-response genes (Michelsen et al., 2004). In the current study, VIP 
treatment in vivo down-regulated IRAK1 and TRAF6 mRNA levels, which is 
consistent with other studies using synovial fibroblasts isolated from patients with 
rheumatoid arthritis: compared with LPS alone, LPS stimulation plus VIP 
treatment inhibited IRAK1 and TRAF6 mRNA and phosphorylated protein 
expression (Arranz et al., 2008b), thereby acting as a negative regulator of TLR4 
signaling. 
Another important signaling complex, the IKK complex, is found 
downstream of IRAK–TRAF6 signaling and is composed of IKKα, IKKβ, and IKKγ 
(Israel, 2010). The current in vivo study showed that VIP inhibited Chuk/IKKα 
mRNA expression, but only modestly decreased its activity, compatible with 
previous in vitro studies showing that VIP directly inhibited IKKα activity in human 
monocytes (Delgado and Ganea, 2001) and microglia cells (Delgado et al., 2008). 
In microglial cells, VIP inhibition of IKKα reduced Aβ-induced neurodegeneration 
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by indirectly inhibiting the production of numerous inflammatory and neurotoxic 
molecules (Delgado et al., 2008). Furthermore, loss or decreased IKKα also was 
suggested to negatively regulate NF-κB and subsequent gene expression by 
inhibiting its translocation to the nucleus and, thus, down-regulating inflammation 
(Anest et al., 2003). 
In contrast to other TLRs, SIGIRR (Wald et al., 2003) and ST2 (Liew et al., 
2005), members of the TLR–IL-1R superfamily, act as negative regulators of IL-1 
and LPS signaling. Previous studies from our laboratory found that SIGIRR 
(Huang et al., 2006b) and ST2 (Huang et al., 2007) promote natural resistance of 
BALB/c versus B6 mice against P. aeruginosa keratitis and that Ab depletion of 
SIGIRR increased disease in BALB/c mice. However, it was not tested whether 
VIP treatment regulates expression of either molecule in susceptible B6 mice. 
The current study showed that in vivo treatment of infected B6 mice with VIP 
increased (but not significantly) SIGIRR mRNA levels over PBS-treated controls 
in normal uninfected eyes; at 1 d p.i., the levels decreased in both groups but 
remained higher with VIP treatment. In previous work from our laboratory (Huang 
et al., 2006b) comparing the expression of SIGIRR in BALB/c versus B6 mice 
after P. aeruginosa infection, we also observed a decrease in mRNA expression 
in both groups at 12 h p.i. (and in B6 mice at 1 d p.i., similar to the current study), 
which increased in both mouse strains later in disease. SIGIRR protein levels 
decreased in the two mouse strains at 1 d p.i. and increased later in disease, 
most significantly in BALB/c mice (Huang et al., 2006b). After in vivo LPS 
challenge, similar consumption of SIGIRR mRNA (protein not tested) was shown 
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by Wald et al. (Wald et al., 2003); they suggested that this may reflect its 
functional involvement in decreasing inflammation. We cited this possibility as 
well but did not prove it functionally (Huang et al., 2006b). The current study 
suggests that a decrease in SIGIRR protein is not required for functionality, 
because we did not observe SIGIRR consumption at the protein level in B6 mice 
treated with VIP; rather, protein levels were increased at 1 d p.i. These data are 
supported by other studies in which overexpression of SIGIRR (adenoviral vector 
expressing murine SIGIRR) was shown to ameliorate LPS-induced acute lung 
injury in mice (Chen et al., 2011); its overexpression in human macrophages and 
dendritic cells downregulated TLR-induced cytokines, whereas its knock down 
increased cytokine production following TLR stimulation (Drexler et al., 2010). In 
contrast, ST2 protein is increased later (7 d p.i.) in disease, suggesting that, after 
VIP treatment, the molecules could act disparately in time to ameliorate disease 
or participate in corneal healing. 
Previous studies on the immunomodulatory properties of VIP led to the 
identification of two pathways: one cAMP dependent and the other cAMP 
independent (Chorny et al., 2006). However, whether VIP regulation of TLRs is 
cAMP dependent or independent had not been tested. To address this issue, we 
silenced AC7 using siRNA, because among the 10 adenyl cyclases it is highly 
expressed in the immune system (Duan et al., 2010). Data showed that VIP 
regulation of TLR1, TRAF6, and ST2 was cAMP dependent, because silencing 
plus VIP treatment did not change the effects of silencing alone. These data 
agree with previous, similarly designed in vitro studies in which a PKA inhibitor 
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was used to block upstream cAMP pathways (Delgado et al., 1999b; Delgado et 
al., 1999c). Data from those studies concluded that VIP regulation of both a 
proinflammatory cytokine TNF-α (Delgado et al., 1999c) and NO (Delgado et al., 
1999b) are cAMP dependent. In contrast, the current study showed that 
regulation of Chuk, IRAK1, IRAK2, TLR4, TLR9, and SIGIRR are cAMP 
independent, because silencing plus VIP treatment changed the effects of 
silencing AC7 alone. These data are consistent with in vitro studies showing that 
VIP can function to regulate molecules, such as NF-κB, in a cAMP-independent 
manner (Delgado and Ganea, 2001). Unexpectedly, compared with scrambled 
control treatment, AC7 siRNA did not induce significant changes in TLR6; 
however, when silencing was combined with VIP treatment, TLR6 levels were 
decreased, suggesting the possibility that other adenyl cyclase isoforms (Song et 
al., 2007) participate in TLR regulation by VIP. 
Previous studies from our laboratory showed the importance of both 
macrophages (McClellan et al., 2003) and Langerhans cells (Hazlett et al., 2002) 
in Pseudomonas keratitis. In this regard, VIP functions as a macrophage-
deactivating factor and was shown to down-regulate pro-inflammatory cytokine 
expression (IL-1β and MIP-2) after LPS (not ultrapure) stimulation in murine 
peritoneal macrophages (Szliter et al., 2007). It also down-regulates pro-
inflammatory cytokine production in epidermal Langerhans cells (Kodali et al., 
2004), but its role in TLR regulation has not been characterized in these types of 
cells. Data from the current study showed that, in peritoneal macrophages and 
XS52 (Langerhans) cells, ultrapure LPS stimulation upregulated TLR1 and TLR4, 
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but VIP plus LPS downregulated both TLRs only in macrophages. These data 
agree with those of other investigators who showed that, compared with LPS 
alone, stimulation of murine macrophages with LPS (not ultrapure) and VIP 
resulted in less TLR4 expression at the transcriptional level (Arranz et al., 2008a); 
however, no similar data are available for XS52 (Langerhans) cells or why they 
respond dissimilarly to macrophages. With regard to TLR1, because other 
investigators showed that cytokines, such as IFN-γ, can increase TLR1 
expression in murine monocytes (Krutzik et al., 2003), we similarly tested for IFN-
γ after ultrapure LPS stimulation of both cell types and found elevated levels, 
which also were decreased by treatment with LPS plus VIP (data not shown). 
With similar treatment, TLR4 downstream-signaling molecules, including MD88, 
IRAK1, and TRAF6, also were down-regulated in macrophages, whereas only 
MyD88 and TRAF6 were down-regulated in XS52 (Langerhans) cells. The 
current study also showed that, compared with LPS treatment alone, LPS 
stimulation plus VIP increased ST2 mRNA expression in macrophages, but only 
SIGIRR was increased in XS52 (Langerhans) cells. These data suggest that VIP 
disparately regulates TLR on these cells and may reflect the kinetics of pathogen 
encounter (ocular surface versus stroma) p.i. in the eye. Despite the differential 
regulation of these cells, it is clear that VIP plus LPS reduces pro-inflammatory 
TLR expression while promoting anti-inflammatory TLR expression. VIP 
treatment in vivo also reduced Langerhans cell centripetal migration and, thus, 
decreased the number of cells in the infected cornea at 1 d p.i. Other 
investigators also showed that VIP treatment inhibits mouse dendritic cell 
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migration to adjacent lymph nodes (Weng et al., 2007), limiting infection. All of 
this is consistent with the anti-inflammatory effects of VIP and with previous 
studies from our laboratory that showed that the presence of Langerhans cells in 
the cornea (before infection) exacerbates subsequent disease (Hazlett et al., 
2002). 
Overall, this study provides evidence that in vivo treatment with VIP down-
regulates pro-inflammatory TLRs and increases anti-inflammatory TLRs and 
related signaling molecule expression via cAMP-dependent and -independent 
pathways, as well as regulates Langerhans cell number and migration in the 
infected cornea. In vitro studies using ultrapure LPS, which only activates the 
TLR4 pathway, confirm the in vivo data and provide evidence that TLR 
expression in macrophages and XS52 (Langerhans) cells is differentially 
regulated by VIP to improve disease outcome. 
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Table 2. Primer sequence of the Toll-like receptors and related molecule for 
Real-Time PCR amplification 
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Table 3. Selected TLRs from RT2 Profiler PCR array 
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FIGURE 11. RT-PCR for mRNA expression. Compared with PBS 
treatment, VIP treatment decreased mRNA levels of TLR1 at 7 d p.i. (A), TLR4 at 
1 d p.i. (B), TLR6 at 5 and 7 d p.i. (C), TLR8 at 7 d p.i. (D), TLR9 at 5 d p.i. (E), 
IRAK1 at 1 and 5 d p.i. (F), TRAF6 at 5 and 7 d p.i. (H), and Chuk at 1 and 7 d p.i. 
(I). VIP versus PBS treatment increased mRNA levels of SIGIRR at 5 and 7 d p.i. 
(J) and for ST2 at 7 d p.i. (K). (G) No significant change was seen for IRAK 2, nor 
were any changes seen at other times tested for any of the assays.  
 
 - 77 -
 
FIGURE 12. ELISA. Compared with PBS treatment, VIP treatment had no 
effect on total IKKα (A) in normal cornea (N) or infected cornea, but it significantly, 
although slightly, decreased p-IKKα protein levels at 7 d p.i. (B), with no effect in 
normal cornea (N) or at 1 d p.i. (C) ST2 protein levels were significantly 
increased by VIP but only at 7 d p.i. (E) Western blot of SIGIRR protein levels in 
the uninfected, normal cornea (N) and infected cornea (1 and 5 d p.i.) of PBS- or 
VIP-treated mice. Equivalent protein was loaded (80 μg/lane) for all lanes except 
lane 1. Lane 1, Murine rSIGIRR (15 ng); lane 2, PBS-treated normal cornea (N); 
lane 3, PBS-treated cornea at 1 d p.i.; lane 4, PBS-treated cornea at 5 d p.i.; lane 
5, VIP-treated normal cornea (N); lane 6, VIP-treated cornea at 1 d p.i.; lane 7, 
VIP-treated cornea at 5 d p.i. (D) The intensity of bands was quantitated and 
normalized to the β-actin control. Data (mean ± SEM integrated density values at 
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each time point) are significant only at 1 d p.i.  
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FIGURE 13. TLR4 immunostaining. At 1 and 5 d p.i., TLR4 staining (red) 
was less intense in the epithelium and stroma after VIP (B, D) treatment 
compared with PBS (A, C) treatment. PBS-treated (E) and VIP-treated (F) 
controls (1 d p.i.), in which the primary Ab was replaced by IgG, were negative for 
TLR4 immunostaining. Original magnification ×100.  
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FIGURE 14. (A) When tested at 5 d p.i., RT-PCR confirmed that, 
compared with scrambled control treatment, silencing AC7 significantly 
decreased AC7 mRNA levels; silencing plus VIP treatment did not reverse the 
effect. When tested at 5 d p.i., silencing AC7 increased mRNA levels of TLR1 (B), 
whereas TRAF6 (C) and ST2 (D) were decreased. Silencing plus VIP injection 
did not change the effect of silencing for any of the above-mentioned molecules. 
In contrast, compared with scrambled control treatment, Chuk (E), IRAK1 (F), 
TLR4 (G), TLR9 (H), and IRAK2 (I) mRNA levels were increased after silencing 
AC7. Silencing plus VIP injection decreased mRNA expression of each of these 
molecules significantly. (J) SIGIRR mRNA levels were decreased after silencing 
AC7; however, silencing plus VIP treatment resulted in increased mRNA levels 
over silencing alone. No significant changes in mRNA levels of TLR6 (K) or TLR8 
(L) were seen with AC7 siRNA treatment; however, silencing plus VIP treatment 
resulted in reduced mRNA levels of TLR6.  
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FIGURE 15.In vitro studies using macrophages. Compared with 
stimulation of macrophages with media control, ultrapure LPS significantly 
increased mRNA levels of TLR1 (A), TLR4 (B), MyD88 (C), IRAK1 (D), and 
TRAF6 (E), whereas it decreased mRNA levels of SIGIRR (F) and had no effect 
on ST2 (G). Compared with LPS alone, LPS plus VIP treatment significantly 
decreased mRNA expression of TLR1 (A), TLR4 (B), MyD88 (C), IRAK1 (D), and 
TRAF6 (E), whereas it increased ST2 (G) and had no effect on SIGIRR (F). 
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Compared with media control, VIP alone had no significant effect on any of the 
molecules tested.  
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FIGURE 16. In vitro studies using XS52 (Langerhans) cells. Compared 
with media control, stimulation of these cells with ultrapure LPS significantly 
increased mRNA levels of TLR1 (A), TLR4 (B), MyD88 (C), and TRAF6 (E), 
whereas it decreased mRNA levels of ST2 (G) and had no effect on IRAK1 (D) or 
SIGIRR (F). Compared with LPS alone, VIP plus LPS treatment significantly 
decreased MyD88 (C) and TRAF6 (E), increased SIGIRR (F), and had no 
significant effect on TLR1 (A), TLR4 (B), IRAK1 (D), or ST2 (G). Cultured cells 
treated with VIP alone did not differ from media-treated controls for any of the 
molecules tested.  
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FIGURE 17. Staining and quantitation of Langerhans cells. In the normal, 
uninfected eye (conjunctiva/peripheral cornea), dendritic-shaped ADPase+ 
Langerhans cells appeared similar in number after VIP (B) or PBS (A) treatment. 
At 1 d p.i., rounded ADPase+ cells in the peripheral cornea appeared to be 
decreased in number after VIP treatment (D) compared with PBS treatment (C). 
At 3 d p.i., cells appeared qualitatively similar after PBS (E) or VIP (F) treatment. 
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Insets show examples of cells. (G) Quantitation confirmed these findings. (A–F) 
Original magnification ×375; field size, 270 μm2.  
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Chapter 4 
THE ROLE OF VIP IN CORNEA 
4.1 Abstract 
Purpose: Exogenous VIP down-regulates pro- but upregulates anti-
inflammatory cytokines, growth factors (GFs) and TLRs promoting healing in 
experimental P. aeruginosa keratitis. Whether VIP is required for GF or GF 
receptor (R) expression in normal and infected cornea is unknown and the 
purpose of this study. Methods: VIP knockout (-/-) and wild type (WT) C57BL/6 
(B6) mice were infected and tested using PCR array, real-time RT-PCR, ELISA 
and immunostaining. VIP antagonist treatment studies also were done using B6 
and BALB/c mice. Results: Infected corneas of VIP-/- vs WT B6 mice perforated 
earlier [2 vs 5 days postinfection (p.i.)] and array data showed that GFs were 
differentially changed between groups. RT-PCR revealed that the infected cornea 
of VIP-/- vs WT mice expressed higher mRNA levels of EGF and HGF, reduced 
FGF, EGFR and HGFR, with no difference in FGFR; differences between groups 
were not seen in normal cornea. Immunostaining for GF and GFR in the normal 
cornea of VIP-/- vs WT mice were similar for both. However, at 1 day p.i., VIP-/- vs 
WT mice had more intense EGF and HGF, similar FGFR, and reduced FGF, 
EGFR, and HGFR staining. VIP antagonist treatment decreased protein levels for 
GFR at 5 days p.i. in both B6 and BALB/c mice, with no significant changes in 
normal cornea. Conclusions: The data show that endogenous VIP is not requisite 
for GF or GFR expression in the normal cornea, but after infection, its absence or 
reduction is critical for their regulation. 
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4.2 Introduction 
P. aeruginosa, an opportunistic, Gram negative pathogen, is one of the 
most virulent organisms associated with microbial keratitis and is often 
associated with contact lens use (Wilhelmus, 1987). Infections progress rapidly 
and lead to inflammatory epithelial edema, stromal infiltration, corneal ulceration, 
and oftentimes vision loss (Hazlett, 2004). Experimental murine models of the 
disease have been established: Th1 responder mouse strains (e.g., C57BL/6, B6) 
are susceptible (cornea perforates), whereas Th2 responder strains (e.g., BALB/c) 
are resistant (cornea heals) (Hazlett et al., 2000). 
In previous studies using these murine models, we provided evidence that 
an anti-inflammatory neuropeptide, VIP promotes resistance against P. 
aeruginosa corneal infection by regulation of cytokine production and subsequent 
alteration of the host inflammatory cell response (Szliter et al., 2007). In addition, 
recent studies from this laboratory have provided mechanistic information that 
VIP treatment modulates keratitis through regulation of growth factors, 
angiogenic molecules, beta defensins (Jiang et al., 2011) and Toll-like receptors 
(TLR) (Jiang el al., 2012) in the infected cornea, contributing to healing. However, 
whether endogenous VIP is required for production of growth factors (GF) or 
growth factor receptors (GFR) in the normal, uninfected cornea and after 
infection remains untested. This is of importance to determine, since it has been 
demonstrated in other experimental models (Ware and Matthay, 2002; 
Woodworth et al., 2005) that one of the ways that inflammation can be regulated 
is through growth factor binding to their receptors. Thus, the current study 
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investigated the expression of growth factors and their receptors in the normal 
and infected cornea of VIP knockout (VIP-/-) vs wild-type (WT) mice. Data from 
the studies provide evidence that the normal cornea of both groups of mice is 
similar morphologically and have a similar pattern of GF and GFR expression, 
suggesting that endogenous VIP is not requisite for their expression. However, 
after infection, corneal perforation occurred more rapidly (2 days p.i.) in knockout 
vs WT mice and real time RT-PCR and immunostaining studies showed 
disparate expression of GF and their receptors in the two groups. As the GFR 
appeared to be most consistently affected, B6 and BALB/c mice were treated 
with a VIP antagonist, infected and tested for GFR expression. In this experiment, 
GFR proteins were reduced for both murine strains, confirming the trend in the 
knockout data. Overall, the current study provides evidence that endogenous VIP 
is not required for normal corneal expression of GF or GFR. However, if it is 
absent or reduced, GFs and their receptors are disregulated and the infected 
cornea perforates rapidly. 
4.3 Materials and Methods 
Infection 
Eight-week-old female C57BL/6, VIP
-/-
 (B6.129S4-Viptm1Clw/J) and BALB/c 
mice, purchased from The Jackson Laboratory (Bar Harbor, ME), were 
anesthetized with ethyl ether and placed beneath a stereoscopic microscope at 
x40 magnification. The cornea of the left eye was wounded (Rudner et al., 2000) 
and a 5-µl aliquot containing 1.0 x 106 CFU of P. aeruginosa (American Type 
Culture Collection, strain 19660, Manassas, VA) was topically delivered. Animals 
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were treated humanely and in compliance with the Association for Research in 
Vision and Ophthalmology Statement on the Use of Animals in Ophthalmic and 
Vision Research. 
Ocular response to bacterial infection 
Corneal disease was graded: (Hazlett et al., 1987) 0 = clear or slight 
opacity, partially or fully covering the pupil; +1 = slight opacity, fully covering the 
anterior segment; +2 = dense opacity, partially or fully covering the pupil; +3 = 
dense opacity, covering the entire anterior segment; and +4 = corneal perforation 
or phthisis. After infection, a clinical score was recorded (days 1 and 2) for each 
group of mice (n = 5/group/treatment). 
VIP antagonist treatment 
BALB/c and B6 mice (n = 5/group/time/assay) were injected 
intraperitoneally with 100 μL PBS containing 10 μg VIP antagonist (McClellan et 
al., 2008) (Bachem, San Carlos, CA) on days −1, 0 (day of infection), and daily 
through 5 days p.i. Control mice were similarly injected with PBS. Normal, 
uninfected and infected corneas were collected at 3 and 5 days p.i. for real-time 
RT-PCR mRNA detection and 5 days p.i. for ELISA assay.  
Real-time RT-PCR 
Total RNA was isolated from an individual cornea using RNA-Stat 60 
(Invitrogen, Carlsbad, CA), per the manufacturer’s recommendations and 
quantitated spectrophotometrically (260 nm). One microgram of total RNA was 
reverse transcribed using MMLV reverse transcriptase. The 20 µl reaction 
mixture containing 200 U of MMLV-reverse transcriptase, 10 U of RNase Inhibitor, 
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500 ng of oligo (dT) primers, 10 mM dNTP, 100 mM DTT, and MMLV reaction 
buffer (Invitrogen, Carlsbad, CA). After, cDNA was amplified using SYBR Green 
Master Mix (Bio-Rad), per the manufacture’s recommendation. Briefly, the 20 µl 
reaction system contained: 10 µl of SYBR Green PCR Master Mix, 0.5 µM 
primers, 2 µl of cDNA (diluted 1/25), and diethyl pyrocarbonate water. All primer 
sets for the PCR array were purchased as a 96-well plate (RT2 Profiler Mouse 
Wound Healing PCR Array; SABiosciences Corporation, Frederick, MD). The 
individual primer sets were designed using PrimerQuest (Integrated DNA 
Technologies, Cambridge, MA). Sequences of primers for　β-actin, EGF, EGFR, 
FGF, FGFR, HGF and HGFR are shown (Table 4).   
Quantitative real-time RT-PCR was performed using the MyiQ single color 
real-time RT-PCR detection system (Bio-Rad). Optimal conditions for PCR 
amplification of cDNA were established using routine methods (Heid et al., 1996). 
Relative mRNA levels were calculated after normalization to β-actin. 
Immunofluorescent staining 
Normal, uninfected and infected eyes were enucleated (n = 3/group/time) 
at 1 day p.i. from WT and VIP-/- mice, immersed in 1X Dulbecco’s PBS 
(Mediatech, Inc., Herndon, VA), embedded in Tissue-Tek OCT compound (Miles, 
Elkhart, IN), and frozen in liquid nitrogen. Ten-micrometer sections were cut, 
mounted to polylysine-coated glass slides, and stored at 37°C overnight. After a 
2 min fixation in acetone, slides were blocked with 10 mM sodium phosphate 
buffer containing 2.5% BSA and donkey IgG (1/100) for 30 min at room 
temperature. Then, sections were incubated for 1 h with goat anti-mouse EGF 
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(15 µg/ml; R&D Systems, Minneapolis, MN) or goat anti-mouse HGF (15 µg/ml; 
R&D Systems) antibody. Antibodies for EGF and HGF were incubated 
simultaneously with antibodies for their receptors, goat anti-mouse EGFR (15 
µg/ml; R&D Systems) or goat anti-mouse HGFR (15 µg/ml; R&D Systems). This 
was followed by secondary antibodies, Alexa Fluor 594-conjugated donkey anti-
goat antibody (for EGF and HGF, respectively, 1/1500; Invitrogen), and Alexa 
Fluor 633-conjugated donkey anti-goat antibody (for EGFR and HGFR, 
respectively, 1/1500; Invitrogen) for another hour.  
Staining for FGF and its receptor, FGFR was done sequentially. After 
incubating the sections with goat anti-mouse FGF antibody (1/100, Santa Cruz 
Biotechnology) for 1 h followed by the secondary Alexa Fluor 633-conjugated 
donkey anti-goat (1/2000; Invitrogen) for another hour, sections were incubated 
with rabbit anti-mouse FGFR AB (1/100, Santa Cruz), 1 h, and Alexa Fluor 546-
conjugated donkey anti-rabbit secondary (1/1500; Invitrogen) for another hour. 
Controls were similarly treated, but the primary Abs were replaced with the same 
host IgG, ChromPure goat or rabbit IgG (Jackson ImmunoResearch 
Laboratories). Finally, sections were visualized and digital images captured with a 
Leica TCS SP2 confocal laser scanning microscope (Leica Microsystems). 
ELISA 
Protein levels for GFR were tested using ELISA kits. Corneas from PBS 
and VIP antagonist treated mice were individually collected (n = 5/group/time) 
from normal uninfected and infected corneas at 5 days p.i. For EGFR (EIAab 
Science Co. Ltd, Wuhan, China), for HGFR (R&D Systems) and for FGFR 
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(MyBioSource, San Diego, CA), corneas were homogenized in 0.5 ml of PBS 
with 0.1% Tween 20 and protease inhibitor (1 tablet/10 ml, Roche). All samples 
were centrifuged at 13,000 rpm for 5 min and an aliquot of each supernatant was 
assayed in duplicate per the manufacturer’s instructions. Sensitivities of the 
ELISA assays were <0.08 ng/ml for EGFR, <10.0 g/ml for HGFR, and <0.1 　
ng/ml for FGFR. 
Statistics 
The difference in clinical score between two groups was tested by the 
Mann-Whitney U test. For all other experiments, an unpaired, two-tailed Student’s 
t test (for comparisons between two groups) was used. P<0.05 was considered 
to be statistically significant.  
4.4  Results 
Ocular response in VIP-/- mice 
VIP-/- vs WT mice showed similar disease scores at 1 day after infection. 
At 2 days p.i., a significantly higher mean clinical score (Fig. 18, p<0.05), 
indicative of worsened disease and/or perforation was recorded for the knockout 
mice. Typical responses for each of the two groups was documented by 
photography using a slit lamp and showed that WT (B) mice had opacity over the 
anterior segment, while VIP-/- (C) mice exhibited corneal perforation, with the 
remainder of the eye heavily opaque due to the presence of an inflammatory 
infiltrate. 
PCR array and real-time RT-PCR 
To determine whether endogenous VIP is required for GF production, 
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mRNA levels of 84 Wound Healing related genes were profiled by PCR array at 1 
day p.i. (Table 5). Eighteen of these GF and related molecules (e.g., EGF, EGFR, 
FGF, and HGF) were differentially changed in VIP-/- vs WT B6 mice and are listed 
in Table 5. RT-PCR was used to selectively confirm the array data and to test for 
FGFR and HGFR which are receptors for FGF and HGF but not included on the 
array. In the normal, uninfected cornea, we found no significant difference at the 
mRNA level between the two mouse groups for GF or GFR expression (Fig. 19 
A-F). However, at 2 days p.i., VIP-/- vs WT mice showed significantly increased 
mRNA levels for EGF (Fig. 19A, p<0.01) and HGF (Fig. 19E, p=0.01) but lower 
levels of FGF (Fig. 19C, p<0.01). For GFR, EGFR (Fig. 19B, p<0.01) and HGFR 
(Fig. 19F, p<0.01) were significantly decreased in VIP-/- vs WT mice, with no 
significant changes to FGFR (Fig. 19D). 
Immunostaining 
Immunostaining confirmed the mRNA data above and showed no 
differences between the two groups of mice in the normal cornea for either the 
GFs (Fig. 20) or for the GFRs (Fig. 21). When comparing the two groups at 1 day 
p.i. (Fig. 22), immunostaining of the cornea of VIP-/- vs WT mice revealed 
increased EGF and HGF, while FGF staining was decreased. For the GFRs, 
comparison in immunostaining between the two groups at 1 day p.i. (Fig. 23) 
revealed that VIP-/- mice had decreased EGFR and HGFR staining, while staining 
for FGFR was similar. All controls (Figs. 20-23) in which the primary antibody was 
replaced with same species IgG, were negative for immuunostaining.  
Real-time RT-PCR 
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Next, to further test the effects of VIP on GF and GFR expression, real-
time RT-PCR was done using B6 mice treated with a VIP antagonist vs PBS. 
Similar to the VIP-/- experiments, there was no significant difference between the 
two groups of mice at the mRNA level in either GFs or GFRs in the normal, 
uninfected cornea (Fig. 24 A-F). However, at 5 days p.i., VIP antagonist vs PBS 
treated mice showed significantly increased mRNA levels for EGF (Fig. 24A, 
p=0.01) and HGF (Fig. 24E, p<0.01), with decreased levels for FGF (Fig. 24C, 
p=0.05). For GFRs, EGFR (Fig. 24B, p=0.01) and HGFR (Fig. 24F, p=0.05) were 
significantly decreased in VIP antagonist vs PBS treated mice, while there was 
no significant change for FGFR (Fig. 24D).   
ELISA 
GFRs were tested at 5 days p.i. in B6 (Fig. 25 A,C,E) and BALB/c (Fig. 25 
B,D,F) mice after treatment with VIP antagonist. For B6 mice, treatment with the 
VIP antagonist resulted in reduced levels of EGFR (A), although not significant, 
while reduction in both FGFR (C, p=0.01) and HGFR (E, p<0.01) were significant. 
For BALB/c mice, VIP antagonist treatment significantly reduced all three GFR, 
EGFR (B, p<0.001), FGFR (D, p<0.01) and HGFR (F, p<0.01). No difference in 
GFRs between groups was detected in normal cornea.  
4.5  Discussion 
The neuropeptide VIP is a multifunctional molecule and regulates immune 
reactions and also participates in the maintenance and restoration of immune 
homeostasis (Souza-Moreira et al., 2011). In addition, VIP has been considered 
in itself to be a growth factor (Gressens et al., 1997), as well as a type 2 cytokine 
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(Pozo and Delgado, 2004).  
In prior work, our laboratory has provided evidence that treatment with 
synthetic VIP regulates expression of pro- and anti-inflammatory cytokines 
(Szliter et al., 2007), growth factors (Jiang et al., 2011), and Toll-like receptors 
(Jiang et al., 2012) in P. aeruginosa induced keratitis. This leads to decreased 
stromal destruction in a B6 mouse model in which the untreated, infected cornea 
perforates within 5-7 days after experimental infection (Szliter et al., 2007). The 
present study, using VIP-/- mice tested whether the endogenous absence of VIP 
or its reduction using an inhibitor, contributed to modulation of growth factors and 
their receptors. No detectable differences in either GFs or GFRs were detected in 
the normal cornea by either RT-PCR or by immunostaining. Neither was there 
detectable differences in corneal morphology between the two groups. In contrast, 
in other models, the absence of VIP has been shown to lead to overall altered 
intestinal morphology, as well as thickening of smooth muscle and increased villi 
length in the bowel (Lelievre et al., 2007). In whole cultured embryonic 9.5 mouse 
embryos, VIP regulated insulin growth factor-I and embryonic development and 
when pregnant mice were treated with a VIP antagonist, inhibition of embryonic 
growth occurred (Servoss et al., 2001).   
After infection, in the absence of the neuropeptide, GFs and GFRs were 
dysregluated when tested by PCR array, RT-PCR and immunostaining and the 
cornea perforated more rapidly (within 2 days after infection) for the majority of 
the knockout vs WT mice. Furthermore, either the endogenous absence of VIP or 
antagonist treatment of B6 mice led to this dysregulation. Specifically, VIP 
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antagonist treatment of B6 mice reduced all three GFRs at the mRNA level (all 
significantly except for FGFR). And when either B6 or BALB/c mice were treated 
with a VIP antagonist, GFR protein levels were decreased in both strains of mice 
when compared with controls. In this regard, others have shown interaction of 
VIP with the EGFR previously. In vitro studies have shown that Gq protein-
coupled receptor agonists such as VIP can directly activate (phosphorylate) the 
EGFR in T84 colonic epithelial cells by signaling pathways involving cAMP and 
protein kinase A and regulate Cl- secretion (Bertelsen et al., 2004). In another 
study, it was reported that during infection of human alveolar epithelial cells with 
Pseudomonas fluorescens, a gram-negative rod, blocking EGFR increased 
epithelial susceptibility to pathogen induced epithelial cell death (Choi et al., 
2011), consistent with, although not tested in our keratitis model. Another growth 
factor, KGF/FGF-7 (FGF) and its receptor (FGFR), were both found to reduce 
Pseudomonas infection in a lung model, through reducing bacterial load, since 
intratracheal FGF was found to increase clearance of P. aeruginosa (Viget et al., 
2000). Another study using an experimental burn model in human keratinocytes, 
also found that when FGF was added to P. aeruginosa in the presence of 
keratinocytes, bacterial growth was inhibited and the same was observed when 
genetically modified keratinocytes were used (Sobral et al., 2007). In addition, P. 
aeruginosa infection in a bioengineered skin model, in which FGF7 was 
expressed in diploid human keratinocytes, led to increased antimicrobial β-
defensin-2 and cathelicidin (LL-37) production and reduced bacterial load when 
compared with controls (Erdag et al., 2004). Previous studies from our laboratory 
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also found that treatment using a GF mixture, composed of EGF, FGF and HGF, 
increased murine beta-defensin-2 (mBD-2) and mBD3 expression, as well as 
decreasing bacterial plate counts, resulting in less disease severity in the 
infected cornea (Jiang et al., 2011). FGF also has been shown to promote wound 
healing in skin epithelium (Marchese et al., 1995) and participates in lung 
epithelial repair as well (Ware and Matthay, 2002). Since many cases of bacterial 
keratitis result either directly or indirectly from disruption of the corneal epithelium 
(O'Brien, 2003), it also is possible that earlier perforation observed in VIP-/- mice 
may be due to reduced FGF levels with subsequent epithelial defect. HGFR 
mRNA and protein (immunostaining) are also decreased in the VIP-/- mice. HGFR 
recognizes HGF which has anti-inflammatory properties, in that it can target 
vascular endothelial cells and disrupt nuclear factor-kappa B (NF-κB) signaling in 
these cells (Gong et al., 2006),critical to regulating inflammatory cytokines.  
Overall, this study provides evidence that although VIP is not required for 
GF and GFR expression in normal cornea, either its absence or reduction results 
in dysregualted GF and GFR expression in the cornea and enhanced disease.  
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Table 4. Primer sequence of the growth factors and their receptors primers for 
Real-Time PCR amplification. 
Gene Primer Sequence (5’ - 3’) Size (bp) 
β-actin 
F – GAT TAC TGC TCT GGC TCC TAG C 
R – GAC TCA TCG TAC TCC TGC TTG C 
147 
EGF 
F – ACG GTT TGC CTC TTT TCC TT 
R – GTT CCA AGC GTT CCT GAG AG 
130 
EFGR 
F – GTG GAG GGA CAT CGT CCA AA 
R – ATT GGG ACA GCT TGG ATC ACA T 
100 
FGF 
F – AAC AGC TAC AAC ATC ATG GAA ATC AG 
R – AAT CAG TTC TTT GAA GTT GCA ATC CT 
153 
FGFR 
F – GTG CTT ATT GGG GAG TAT CTC CA 
R – GAT CCA AGT TTC ACT GTC TAC CG 
102 
HGF 
F – ACT TCT GCC GGT CCT GTT G 
R – GGG ATG GCG ACA TGA AGC A 
66 
HGFR 
F – GTG AAC ATG AAG TAT CAG CTC CC 
R – TGT AGT TTG TGG CTC CGA GAT 
100 
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Table 5. Selected GFs from The Mouse Wound Healing RT2 ProfilerTM PCR array 
1.27  Vegfa 
1.92  Tnf 
1.45  Tgfb1 
-2.03  Tgfa 
1.16  Pdgfa 
1.21  Mif 
-3.63  Igf1 
1.25  Hgf 
-2.11  Hbegf 
-5.03  Fgf7 
-1.41  Fgf2 
4.69  Fgf10 
-1.83  Egfr 
1.47  Egf 
-2.06  Ctgf 
1.03  Csf3 
-1.79  Csf2 
-6.45  Angpt1 
VIP-/- / WT 
Fold  
Differences 
 
 
Genes 
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Figure 18. VIP-/- and WT B6 mice. Clinical scores (A) indicated statistically 
significant differences at 2 days p.i. between groups. Photographs taken with a 
slit lamp at 2 days p.i. showed an early perforation in VIP-/- (C) vs WT (B) mice. 
Magnification = ×7. 
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Figure 19. GF and GFR mRNA expression. At 2 days p.i., EGF (A) and HGF (E) 
were significantly increased, while FGF (C) mRNA levels were significantly 
decreased in VIP-/- vs WT mice. EGFR (B) and HGFR (F) were decreased 
significantly, while FGFR (D) mRNA was similar in the two groups. No significant 
changes between the two groups were seen in normal cornea. 
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Figure 20. GF immunostaining in normal cornea. GF staining was similar in VIP-/- 
and WT B6 mice. Negative controls, in which the primary antibody was replaced 
with a species-specific IgG, showed no positive staining. Magnification = 170X 
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Figure 21. GFR immunostaining in normal cornea. GFR staining did not 
difference between VIP-/- and WT B6 mice. Negative controls, in which the 
primary antibody was replaced with a species-specific IgG, showed no positive 
staining. Magnification = 170X 
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Figure 22. GF immunostaining at 1 day p.i. Greater staining intensity for EGF 
and HGF, with reduced intensity for FGF was seen in VIP-/- compared to WT B6 
mice. Negative controls, in which the primary antibody was replaced with a 
species-specific IgG, showed no positive staining. Magnification = 170X. 
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Figure 23. GFR immunostaining at 1 day p.i. Staining for GFRs was less intense 
for EGFR and HGFR in VIP-/- compared to WT B6 mice. No difference for FGFR 
was noted between groups. Negative controls, in which the primary antibody was 
replaced with a species-specific IgG, showed no positive staining. Magnification = 
170X. 
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Figure 24. GF and GFR mRNA expression. EGF (A) and HGF (E) were 
significantly increased, while FGF (C) was decreased in VIP antagonist treated 
B6 mice at 5 days p.i. EGFR (B) and HGFR (F) were significantly decreased with 
no difference in FGFR (D) after VIP antagonist treatment. No difference was 
detected between groups in normal, uninfected cornea. 
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Figure 25. GFR ELISA analysis. VIP antagonist vs PBS treatment decreased 
GFR (A-F) in both B6 and BALB/c mice at 5 days p.i. All were significant except 
for EGFR (A). No significant changes were seen in the normal cornea between 
two groups. 
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Chapter 5 
CONCLUSIONS 
Host immunity has been considered as an important factor in determining 
the prognosis of microbial keratitis (Hazlett LD et al., 2004). Previous study has 
found that VIP promoted resistance against P. aeruginosa induced corneal 
infection by regulating cytokine production and subsequently altering the host 
inflammatory response (Szliter et al., 2007). However, the role of VIP in 
regulation of growth factors and TLRs during P. aeruginosa keratitis remained 
untested. In this regard, current studies provide important insights showing that 
VIP modulates growth factors and TLR signaling in the infected cornea and these 
in turn, contribute to better disease outcome.  
In chapter 2 (This part of the work has been published: Jiang et al., 2011), 
we found that VIP vs PBS treatment increased growth factor and angiogenic 
molecules mRNA and protein levels in infected B6 mouse cornea. In order to 
assess whether the anti-inflammatory effect of VIP was through regulating growth 
factors, a mixture of EGF, FGF and HGF was topically applied after infection. 
Treatment with a mixture of growth factors prevents corneal perforation, down-
regulated pro-inflammatory cytokines but up-regulated anti-inflammatory 
cytokines and β defensins, as well as delaying bacterial growth, indicating the 
anti-inflammatory effects of VIP are partially achieved through regulating growth 
factor production.  
In chapter 3 (This part of work has been published: Jiang et al., 2012), our 
work provided evidence that VIP vs PBS treatment decreased pro-inflammatory 
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TLRs but increased anti-inflammatory TLRs in infected B6 mouse cornea and 
also in XS52 (Langerhans) cells and peritoneal macrophages. To determine 
whether VIP effects were cAMP dependent, mice were injected with AC7 siRNA 
with or without VIP treatment and tested for TLR and related molecules mRNA 
expression. The results indicated that VIP regulates TLR1, TRAF6 and ST2 in a 
cAMP dependent manner, but Chuk, IRAK1, 2, TLR4, 9 and SIGIRR were found 
to be cAMP independent. Moreover, we found that exogenous VIP treatment, 
compared to PBS control, reduced Langerhans cell number in early (1 day p.i.) 
infected cornea. 
In chapter 4 (This part of work has been submitted for publication and is in 
revision, 2012), we investigated whether VIP is required for expression of growth 
factors and their receptors in normal and infected cornea. Our data provide solid 
evidence of the importance of VIP in host resistance against corneal P. 
aeruginosa infection. We observed that VIP-/- vs WT B6 mouse corneas showed 
more severe infection and earlier perforation. PCR array and real time RT-PCR 
data indicated that growth factors and their receptors were differentially changed 
in infected VIP-/- vs WT mouse cornea; differences between groups were not 
seen in normal cornea. Immunostaining for growth factors and their receptors in 
normal and infected cornea of both groups of mice showed similar results when 
compared with the mRNA data. Additionally, VIP antagonist treatment decreased 
protein levels for growth factor receptors at 5 days p.i. in both B6 and BALB/c 
mice, with no significant changes in normal cornea. These results indicate that 
endogenous VIP is not required for the expression of growth factors and their 
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receptors in normal cornea, but critical for their regulation after infection. 
In summary, this dissertation has focused upon how VIP regulates host 
immunity to promote resistance against corneal infection. Our data suggest that 
VIP modulates growth factors and their receptors as well as TLR expression, 
contributing to corneal healing. The findings presented herein provide further 
evidence to justify testing VIP clinically either alone, or with antibiotics, to treat 
microbial keratitis.  
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The purpose of the current dissertation was to examine how VIP regulates 
host immunity and corneal healing, specifically, its control of growth factors and 
TLR expression in the P. aeruginosa infected cornea. Firstly, VIP treatment 
increased growth factor expression (EGF, HGF, FGF and VEGF) in infected 
cornea. Notably, treatment with a mixture of EGF, FGF and HGF prevented 
corneal perforation, reduced pro-inflammatory cytokines and bacterial plate count, 
while increasing anti-inflammatory cytokines and antimicrobials such as murine 
β-defensin2 and 3.  
We also investigated the expression of TLR-signaling pathways in P. 
aeruginosa-infected corneas with or without VIP treatment. PCR array and real-
time RT-PCR data demonstrated that VIP treatment decreased pro-inflammatory, 
but increased anti-inflammatory TLRs. Immunohistochemistry, ELISA and 
western blot results further confirmed the PCR data. AC7 siRNA experiments 
indicated that VIP regulated TLR1, TRAF6 and ST2 in a cAMP dependent 
manner, but Chuk, IRAK1, 2, TLR4, 9 and SIGIRR were cAMP independent. In 
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vitro, VIP down-regulated pro-inflammatory, but increased anti-inflamamtory 
TLRs in macrophages and Langerhans (XS52) cells. Exogenous VIP also 
decreased Langerhans cell number in the infected cornea. 
Furthermore, we used VIP-/- mice to asses whether VIP is required for 
expression of growth factors and their receptors in normal and infected cornea. 
VIP-/- vs WT B6 mice showed earlier corneal perforation. PCR array showed 
growth factors are differentially changed between groups. Real time RT-PCR and 
immunostaining studies revealed that the infected cornea of VIP-/- vs WT mice 
expressed higher EGF and HGF, reduced FGF, EGFR and HGFR and similar 
FGFR; no significant difference between the two groups of mice were seen in 
normal cornea. VIP antagonist treatment decreased protein levels for growth 
factor receptors at 5 days p.i. in both B6 and BALB/c mice, with no significant 
changes in normal cornea. 
In summary, these data provide evidence that VIP modulate growth factors, 
angiogenic molecules and beta defensins in the infected cornea; that it reduced 
pro-inflammatory, but increased anti-inflammatory TLRs after corneal infection; 
and that it is not required for growth factor production in the normal cornea but 
required in the infected cornea to delay perforation.  
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